Combination of SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE INGREDIENTS FOR USE IN THE TREATMENT OF HEMATOLOGICAL MALIGNITY

Description

[0001] This application claims priority to U.S. Provisional Application No. 62 / 923,945, filed on October 21, 2019.1. FIELD

[0002] Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing hematological malignancies.2. BACKGROUND

[0003] Cancer is characterized primarily by an increase in the number of abnormal cells derived from a given normal tissue, invasion of adjacent tissues by these abnormal cells, or lymphatic or blood-borne spread of malignant cells to regional lymph nodes and metastasis. Clinical data and molecular biologic studies indicate that cancer is a multistep process that begins with minor preneoplastic changes, which may under certain conditions progress to neoplasia. The neoplastic lesion may evolve clonally and develop an increasing capacity for invasion, growth, metastasis, and heterogeneity, especially under conditions in which the neoplastic cells escape the host's immune surveillance. Current cancer therapy may involve surgery, chemotherapy, hormonal therapy and / or radiation treatment to eradicate neoplastic cells in a patient. Recent advances in cancer therapeutics are discussed by Rajkumar et al. in Nature Reviews Clinical Oncology 11, 628-630 (2014).

[0004] All of the current cancer therapy approaches pose significant drawbacks for the patient. Surgery, for example, may be contraindicated due to the health of a patient or may be unacceptable to the patient. Additionally, surgery may not completely remove neoplastic tissue. Radiation therapy is only effective when the neoplastic tissue exhibits a higher sensitivity to radiation than normal tissue. Radiation therapy can also often elicit serious side effects. Hormonal therapy is rarely given as a single agent. Although hormonal therapy can be effective, it is often used to prevent or delay recurrence of cancer after other treatments have removed the majority of cancer cells.

[0005] Despite availability of a variety of chemotherapeutic agents, chemotherapy has many drawbacks. Almost all chemotherapeutic agents are toxic, and chemotherapy causes significant, and often dangerous side effects including severe nausea, bone marrow depression, and immunosuppression. Additionally, even with administration of combinations of chemotherapeutic agents, many tumor cells are resistant or develop resistance to the chemotherapeutic agents. In fact, those cells resistant to the particular chemotherapeutic agents used in the treatment protocol often prove to be resistant to other drugs, even if those agents act by different mechanism from those of the drugs used in the specific treatment. This phenomenon is referred to as pleiotropic drug or multidrug resistance. Because of the drug resistance, many cancers prove or become refractory to standard chemotherapeutic treatment protocols.

[0006] Hematological malignancies are cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematological malignancies are leukemia, lymphoma, and myeloma. More specific examples of hematological malignancies include but are not limited to acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma (HL), T-cell lymphoma (TCL), Burkitt lymphoma (BL), chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), marginal zone lymphoma (MZL), and myelodysplastic syndromes (MDS).3. SUMMARY

[0007] The invention is set out in the appended set of claims. Any references in the description to methods of treatment refer to the compounds, pharmaceutical compositions and medicaments of the present invention for use in a method for treatment of the human (or animal) body by therapy (or for diagnosis). Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (Compound 1), or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing hematological malignancies, wherein the second active agent is one or more of an HDAC inhibitor (e.g., panobinostat, romidepsin, vorinostat, or citarinostat), a BCL2 inhibitor (e.g., venetoclax), a BTK inhibitor (e.g., ibrutinib or acalabrutinib), an mTOR inhibitor (e.g., everolimus), a PI3K inhibitor (e.g., idelalisib), a PKCβ inhibitor (e.g., enzastaurin), a SYK inhibitor (e.g., fostamatinib), a JAK2 inhibitor (e.g., fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib), an Aurora kinase inhibitor (e.g., alisertib), an EZH2 inhibitor (e.g., tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A, EPZ005687, EI1, UNC1999, or sinefungin), a BET inhibitor (e.g., birabresib or Compound B), a hypomethylating agent (e.g., 5-azacytidine or decitabine), a DOT1L inhibitor (e.g., pinometostat), a HAT inhibitor (e.g., C646), a WDR5 inhibitor (e.g., OICR-9429), a DNMT1 inhibitor (e.g., GSK3484862), an LSD-1 inhibitor (e.g., Compound C or seclidemstat), a G9A inhibitor (e.g., UNC 0631), a PRMT5 inhibitor (e.g., GSK3326595), a BRD inhibitor (e.g., LP99), a SUV420H1 / H2 inhibitor (e.g., A-196), a CARM1 inhibitor (e.g., EZM2302), a PLK1 inhibitor (e.g., BI2536), an NEK2 inhibitor (e.g., JH295), an MEK inhibitor (e.g., trametinib), a PHF19 inhibitor, a PIM inhibitor (e.g., LGH-447), an IGF-1R inhibitor (e.g., linsitinib), an XPO1 inhibitor (e.g., selinexor), a BIRC5 inhibitor (e.g., YM155), or a chemotherapy (e.g., bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone). Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is also collectively referred to as "Compound A".

[0008] Also provided for use in the methods provided herein are pharmaceutical compositions formulated for administration by an appropriate route and means containing effective concentrations of a compound provided herein, for example, Compound A, and optionally comprising at least one pharmaceutical carrier. In one embodiment, the compound provided herein is Compound 1.

[0009] In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the treatment of a hematological malignancy provided herein in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the prevention of a hematological malignancy provided herein in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the amelioration of a hematological malignancy provided herein in combination with the second active agent provided herein.

[0010] In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the treatment of a hematological malignancy provided herein in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the prevention of a hematological malignancy provided herein in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the amelioration of a hematological malignancy provided herein in combination with the second active agent provided herein.

[0011] In one embodiment, the hematological malignancy is acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma (HL), T-cell lymphoma (TCL), Burkitt lymphoma (BL), chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), marginal zone lymphoma (MZL), or myelodysplastic syndromes (MDS).

[0012] In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the treatment of AML in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the prevention of AML in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the amelioration of AML in combination with the second active agent provided herein.

[0013] In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the treatment of AML in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the prevention of AML in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the amelioration of AML in combination with the second active agent provided herein.

[0014] In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the treatment of ALL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the prevention of ALL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the amelioration of ALL in combination with the second active agent provided herein.

[0015] In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the treatment of ALL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the prevention of ALL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the amelioration of ALL in combination with the second active agent provided herein.

[0016] In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the treatment of MM in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the prevention of MM in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the amelioration of MM in combination with the second active agent provided herein.

[0017] In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the treatment of MM in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the prevention of MM in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the amelioration of MM in combination with the second active agent provided herein.

[0018] In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the treatment of NHL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the prevention of NHL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the amelioration of NHL in combination with the second active agent provided herein.

[0019] In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the treatment of NHL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the prevention of NHL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the amelioration of NHL in combination with the second active agent provided herein.

[0020] In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the treatment of DLBCL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the prevention of DLBCL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the amelioration of DLBCL in combination with the second active agent provided herein.

[0021] In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the treatment of DLBCL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the prevention of DLBCL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the amelioration of DLBCL in combination with the second active agent provided herein.

[0022] In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the treatment of HL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the prevention of HL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the amelioration of HL in combination with the second active agent provided herein.

[0023] In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the treatment of HL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the prevention of HL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the amelioration of HL in combination with the second active agent provided herein.

[0024] In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the treatment of TCL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the prevention of TCL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the amelioration of TCL in combination with the second active agent provided herein.

[0025] In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the treatment of TCL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the prevention of TCL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the amelioration of TCL in combination with the second active agent provided herein.

[0026] In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the treatment of BL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the prevention of BL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the amelioration of BL in combination with the second active agent provided herein.

[0027] In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the treatment of BL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the prevention of BL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the amelioration of BL in combination with the second active agent provided herein.

[0028] In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the treatment of CLL / SLL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the prevention of CLL / SLL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the amelioration of CLL / SLL in combination with the second active agent provided herein.

[0029] In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the treatment of CLL / SLL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the prevention of CLL / SLL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the amelioration of CLL / SLL in combination with the second active agent provided herein.

[0030] In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the treatment of MZL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the prevention of MZL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the amelioration of MZL in combination with the second active agent provided herein.

[0031] In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the treatment of MZL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the prevention of MZL in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the amelioration of MZL in combination with the second active agent provided herein.

[0032] In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the treatment of MDS in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the prevention of MDS in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound A effective for the amelioration of MDS in combination with the second active agent provided herein.

[0033] In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the treatment of MDS in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the prevention of MDS in combination with the second active agent provided herein. In one embodiment, the pharmaceutical compositions deliver amounts of Compound 1 effective for the amelioration of MDS in combination with the second active agent provided herein.

[0034] The compounds or compositions provided herein, or pharmaceutically acceptable derivatives thereof, may be administered simultaneously with, prior to, or after administration of each other and one or more of the above therapies.

[0035] These and other aspects of the subject matter described herein will become evident upon reference to the following detailed description.4. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] FIG. 1 shows sensitivity of DLBCL cell line proliferation to Compound 1 treatment, as measured by a Cell Titer Glo assay. FIG. 2 shows heat map of additive (light greay) and synergy (dark grey) scoring of combination treatments of hematological malignancies cell lines with Compound 1 and second active agents. FIG. 3 shows anti-tumor activity of Compound 1 alone and in combination with 5-azacytidine in WSU-DLCL2 (DLBCL) xenograft model. FIG. 4 shows anti-tumor activity of Compound 1 alone and in combination with tazemetostat in WSU-DLCL2 (DLBCL) xenograft model. FIG. 5A, FIG. 5B, and FIG. 5C show anti-tumor activity of Compound 1 (at 3, 10, and 30 mg / kg respectively) alone and in combination with tazemetostat in DB (DLBCL) xenograft model. FIG. 6 shows heat map of normalized percentage of tumor cells treated with Compound 1 in combination with venetoclax. FIG. 7 shows heat map of normalized percentage of tumor cells treated with Compound 1 in combination with ibrutinib. FIG. 8 shows heat map of additive and synergy scoring of combination treatments of DLBCL cell lines with Compound 1 and Compound B. 5. DETAILED DESCRIPTION OF THE INVENTION 5.1 Definitions

[0037] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

[0038] As used herein, and in the specification and the accompanying claims, the indefinite articles "a" and "an" and the definite article "the" include plural as well as single referents, unless the context clearly indicates otherwise.

[0039] As used herein, the terms "comprising" and "including" can be used interchangeably. The terms "comprising" and "including" are to be interpreted as specifying the presence of the stated features or components as referred to, but does not preclude the presence or addition of one or more features, or components, or groups thereof. Additionally, the terms "comprising" and "including" are intended to include examples encompassed by the term "consisting of". Consequently, the term "consisting of" can be used in place of the terms "comprising" and "including" to provide for more specific embodiments of the invention.

[0040] The term "consisting of" means that a subject-matter has at least 90%, 95%, 97%, 98% or 99% of the stated features or components of which it consists. In another embodiment the term "consisting of" excludes from the scope of any succeeding recitation any other features or components, excepting those that are not essential to the technical effect to be achieved.

[0041] As used herein, the term "or" is to be interpreted as an inclusive "or" meaning any one or any combination. Therefore, "A, B or C" means any of the following: "A; B; C; A and B; A and C; B and C; A, B and C". An exception to this definition will occur only when a combination of elements, functions, steps or acts are in some way inherently mutually exclusive.

[0042] As used herein, and unless otherwise specified, the terms "about" and "approximately," when used in connection with doses, amounts, or weight percents of ingredients of a composition or a dosage form, mean a dose, amount, or weight percent that is recognized by one of ordinary skill in the art to provide a pharmacological effect equivalent to that obtained from the specified dose, amount, or weight percent. In certain embodiments, the terms "about" and "approximately," when used in this context, contemplate a dose, amount, or weight percent within 30%, within 20%, within 15%, within 10%, or within 5%, of the specified dose, amount, or weight percent.

[0043] As used herein, and unless otherwise specified, the term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable, relatively non-toxic acids, including inorganic acids and organic acids. In certain embodiments, suitable acids include, but are not limited to, acetic, adipic, 4-aminosalicylic, ascorbic, aspartic, benzenesulfonic, benzoic, camphoric, camphorsulfonic, capric, caproic, caprylic, cinnamic, carbonic, citric, cyclamic, dihydrogenphosphoric, 2,5-dihydroxybenzoic (gentisic), 1,2-ethanedisulfonic, ethanesulfonic, fumaric, galactunoric, gluconic, glucuronic, glutamic, glutaric, glycolic, hippuric, hydrobromic, hydrochloric, hydriodic, isobutyric, isethionic, lactic, maleic, malic, malonic, mandelic, methanesulfonic, monohydrogencarbonic, monohydrogen-phosphoric, monohydrogensulfuric, mucic, 1,5-naphthalenedisulfonic, nicotinic, nitric, oxalic, pamoic, pantothenic, phosphoric, phthalic, propionic, pyroglutamic, salicylic, suberic, succinic, sulfuric, tartaric, toluenesulfonic acid, and the like (see, e.g., S. M. Berge et al., J. Pharm. Sci., 66:1-19 (1977); and Handbook of Pharmaceutical Salts: Properties, Selection and Use, P. H. Stahl and C. G. Wermuth, Eds., (2002), Wiley, Weinheim). In certain embodiments, suitable acids are strong acids (e.g., with pKa less than about 1), including, but not limited to, hydrochloric, hydrobromic, sulfuric, nitric, methanesulfonic, benzene sulfonic, toluene sulfonic, naphthalene sulfonic, naphthalene disulfonic, pyridine-sulfonic, or other substituted sulfonic acids. Also included are salts of other relatively non-toxic compounds that possess acidic character, including amino acids, such as aspartic acid and the like, and other compounds, such as aspirin, ibuprofen, saccharin, and the like. Acid addition salts can be obtained by contacting the neutral form of a compound with a sufficient amount of the desired acid, either neat or in a suitable solvent.

[0044] As used herein, and unless otherwise specified, the term "prodrug" of an active compound refers to compounds that are transformed in vivo to yield the active compound or a pharmaceutically acceptable form of the active compound. A prodrug can be inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis (e.g., hydrolysis in blood). Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively.

[0045] As used herein, and unless otherwise specified, the term "isomer" refers to different compounds that have the same molecular formula. "Stereoisomers" are isomers that differ only in the way the atoms are arranged in space. "Atropisomers" are stereoisomers from hindered rotation about single bonds. "Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. A mixture of a pair of enantiomers in any proportion can be known as a "racemic" mixture. "Diastereoisomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry can be specified according to the Cahn-Ingold-Prelog R-S system. When a compound is an enantiomer, the stereochemistry at each chiral carbon can be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. However, the sign of optical rotation, (+) and (-), is not related to the absolute configuration of the molecule, R and S. Certain of the compounds described herein contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry at each asymmetric atom, as (R)- or (S)-. The present chemical entities, pharmaceutical compositions and methods are meant to include all such possible isomers, including racemic mixtures, optically substantially pure forms and intermediate mixtures. Optically active (R)- and (S)- isomers can be prepared, for example, using chiral synthons or chiral reagents, or resolved using conventional techniques.

[0046] "Stereoisomers" can also include E and Z isomers, or a mixture thereof, and cis and trans isomers or a mixture thereof. In certain embodiments, a compound described herein is isolated as either the E or Z isomer. In other embodiments, a compound described herein is a mixture of the E and Z isomers.

[0047] "Tautomers" refers to isomeric forms of a compound that are in equilibrium with each other. The concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether the compound is a solid or is in an organic or aqueous solution. For example, in aqueous solution, pyrazoles may exhibit the following isomeric forms, which are referred to as tautomers of each other:

[0048] It should also be noted a compound described herein can contain unnatural proportions of atomic isotopes at one or more of the atoms. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3< H), iodine-125 ( 125< I), sulfur-35 ( 35< S), or carbon-14 ( 14< C), or may be isotopically enriched, such as with deuterium ( 2< H), carbon-13 ( 13< C), or nitrogen-15 ( 15< N). As used herein, an "isotopolog" is an isotopically enriched compound. The term "isotopically enriched" refers to an atom having an isotopic composition other than the natural isotopic composition of that atom. "Isotopically enriched" may also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of that atom. The term "isotopic composition" refers to the amount of each isotope present for a given atom. Radiolabeled and isotopically enriched compounds are useful as therapeutic agents, e.g., cancer therapeutic agents, research reagents, e.g., binding assay reagents, and diagnostic agents, e.g., in vivo imaging agents. All isotopic variations of a compound described herein, whether radioactive or not, are intended to be encompassed within the scope of the embodiments provided herein. In some embodiments, there are provided isotopologs of a compound described herein, for example, the isotopologs are deuterium, carbon-13, and / or nitrogen-15 enriched. As used herein, "deuterated", means a compound wherein at least one hydrogen (H) has been replaced by deuterium (indicated by D or 2< H), that is, the compound is enriched in deuterium in at least one position.

[0049] It should be noted that if there is a discrepancy between a depicted structure and a name for that structure, the depicted structure is to be accorded more weight.

[0050] As used herein and unless otherwise indicated, the term "treating" means an alleviation, in whole or in part, of a disorder, disease or condition, or one or more of the symptoms associated with a disorder, disease, or condition, or slowing or halting of further progression or worsening of those symptoms, or alleviating or eradicating the cause(s) of the disorder, disease, or condition itself.

[0051] As used herein and unless otherwise indicated, the term "preventing" means a method of delaying and / or precluding the onset, recurrence or spread, in whole or in part, of a disorder, disease or condition; barring a subject from acquiring a disorder, disease, or condition; or reducing a subject's risk of acquiring a disorder, disease, or condition.

[0052] As used herein and unless otherwise indicated, the term "managing" encompasses preventing the recurrence of the particular disease or disorder in a patient who had suffered from it, lengthening the time a patient who had suffered from the disease or disorder remains in remission, reducing mortality rates of the patients, and / or maintaining a reduction in severity or avoidance of a symptom associated with the disease or condition being managed.

[0053] As used herein and unless otherwise indicated, the term "effective amount" in connection with a compound means an amount capable of treating, preventing, or managing a disorder, disease or condition, or symptoms thereof.

[0054] As used herein and unless otherwise indicated, the term "subject" or "patient" includes an animal, including, but not limited to, an animal such a cow, monkey, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or guinea pig, in one embodiment a mammal, in another embodiment a human.

[0055] As used herein and unless otherwise indicated, the term "relapsed" refers to a disorder, disease, or condition that responded to treatment (e.g., achieved a complete response) then had progression. The treatment can include one or more lines of therapy. In one embodiment, the disorder, disease or condition has been previously treated with one or more lines of therapy. In another embodiment, the disorder, disease or condition has been previously treated with one, two, three or four lines of therapy. In some embodiments, the disorder, disease or condition is a hematological malignancy.

[0056] In one embodiment, "relapsed" DLBCL may refer to DLBCL that has been previously treated with one or more lines of therapy. In one embodiment, the relapsed DLBCL is DLBCL that has been previously treated with one, two, three or four lines of therapy. In one embodiment, the relapsed DLBCL is DLBCL that has been previously treated with two or more lines of treatment.

[0057] As used herein and unless otherwise indicated, the term "refractory" refers to a disorder, disease, or condition that has not responded to prior treatment that can include one or more lines of therapy. In one embodiment, the disorder, disease, or condition has been previously treated one, two, three or four lines of therapy. In one embodiment, the disorder, disease, or condition has been previously treated with two or more lines of treatment, and has less than a complete response (CR) to most recent systemic therapy containing regimen. In some embodiments, the disorder, disease or condition is a hematological malignancy.

[0058] In one embodiment, "relapsed or refractory" CLL / SLL may refer to CLL / SLL that has been previously treated with one or more lines of therapy. In one embodiment, the relapsed or refractory CLL / SLL is CLL / SLL that has been previously treated with one, two, three or four lines of therapy. In one embodiment, the relapsed or refractory CLL / SLL is CLL / SLL that has been previously treated with two or more lines of therapy. In one embodiment, the relapsed or refractory CLL / SLL is CLL / SLL that has been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor. In one embodiment, the relapsed or refractory CLL / SLL is relapsed or refractory to a BTK inhibitor. In one embodiment, the BTK inhibitor is ibrutinib. In one embodiment, the BTK inhibitor is acalabrutinib. In one embodiment, the BTK inhibitor is zanubrutinib. In one embodiment, the BTK inhibitor is tirabrutinib.

[0059] In the context of a cancer, for example, a hematological malignancy, inhibition may be assessed by inhibition of disease progression, inhibition of tumor growth, reduction of primary tumor, relief of tumor-related symptoms, inhibition of tumor secreted factors, delayed appearance of primary or secondary tumors, slowed development of primary or secondary tumors, decreased occurrence of primary or secondary tumors, slowed or decreased severity of secondary effects of disease, arrested tumor growth and regression of tumors, increased Time To Progression (TTP), increased Progression Free Survival (PFS), increased Overall Survival (OS), among others. OS as used herein means the time from treatment onset until death from any cause. TTP as used herein means the time from treatment onset until tumor progression; TTP does not include deaths. In one embodiment, PFS means the time from treatment onset until tumor progression or death. In one embodiment, PFS means the time from the first dose of compound to the first occurrence of disease progression or death from any cause. In one embodiment, PFS rates are computed using the Kaplan-Meier estimates. Event-free survival (EFS) means the time from treatment onset until any treatment failure, including disease progression, treatment discontinuation for any reason, or death. In one embodiment, overall response rate (ORR) means the percentage of patients who achieve a response. In one embodiment, ORR means the sum of the percentage of patients who achieve complete and partial responses. In one embodiment, ORR means the percentage of patients whose best response ≥ partial response (PR). In one embodiment, duration of response (DoR) is the time from achieving a response until relapse or disease progression. In one embodiment, DoR is the time from achieving a response ≥ partial response (PR) until relapse or disease progression. In one embodiment, DoR is the time from the first documentation of a response until to the first documentation of progressive disease or death. In one embodiment, DoR is the time from the first documentation of a response ≥ partial response (PR) until to the first documentation of progressive disease or death. In one embodiment, time to response (TTR) means the time from the first dose of compound to the first documentation of a response. In one embodiment, TTR means the time from the first dose of compound to the first documentation of a response ≥ partial response (PR). In the extreme, complete inhibition, is referred to herein as prevention or chemoprevention. In this context, the term "prevention" includes either preventing the onset of clinically evident cancer altogether or preventing the onset of a preclinically evident stage of a cancer. Also intended to be encompassed by this definition is the prevention of transformation into malignant cells or to arrest or reverse the progression of premalignant cells to malignant cells. This includes prophylactic treatment of those at risk of developing a cancer.

[0060] In certain embodiments, the treatment of NHL may be assessed by the International Workshop Criteria for Malignant Lymphoma (see Cheson et al., J. Clin. Oncol.. 2014, 32(27):3059-3068) and the Deauville Criteria for fluorodeoxyglucose-positron emission tomography (FDG-PET) scan interpretation (Itti et al., Eur. J. Nucl. Med. Mol. Imaging, 2013, 40(9):1312-20; Meignan et al., Leuk Lymphoma, 2014, 55(1):31-37) ("Lugano criteria"), using the response and end point definition shown in Tables 1-3. Table 1. Criteria for Involvement of Site.Tissue Site Clinical FDG Avidity Test Positive Finding Lymph nodesPalpableFDG-avid histologiesPET / CTIncrease FDG uptakeNonavid diseaseCTUnexplained node enlargementSpleenPalpableFDG-avid histologiesPET / CTDiffuse uptake, solitary mass, miliary lesions, nodulesNonavid diseaseCT> 13 cm in vertical length, mass, nodulesLiverPalpableFDG-avid histologiesPET / CTDiffuse uptake, massNonavid diseaseCTNodulesCNSSigns, symptomsN / ACTMass lesion(s)MRILeptomeningeal infiltration, mass lesionsCSF assessmentCytology, flow cytometryOther (eg, skin, lung, GI tract, bone, bone marrow)Site dependentN / APET / CT a< , biopsyLymphoma involvementCNS = central nervous system; CSF = cerebrospinal fluid; CT = computed tomography; FDG = fluorodeoxyglucose; GI = gastrointestinal; MRI = magnetic resonance imaging; PET = positron emission tomography; N / A = not applicable. a< PET / CT is adequate for determination of bone marrow involvement and can considered highly suggestive for involvement of other extralymphatic sites. Biopsy confirmation of those sites can be considered if necessary. Table 2. Lugano Response Criteria for Non-Hodgkin Lymphoma. Response Site PET / CT (metabolic response) CT (Radiologic response) Complete responseLymph nodes and extralymphatic sitesScore 1, 2, 3 with or without residual mass on 5-PS (Table 3)All of the following:Target nodes / nodal masses must regress to ≤ 1.5 cm in LDiNo extralymphatic sites of diseaseNon-measured lesionN / AAbsentOrgan enlargementN / ARegress to normalNew LesionsNoneNoneBone MarrowNo evidence of FDG-avid disease in marrowNormal by morphology; if inderterminate, IHC negative a< Partial ResponseLymph nodes and extralymphatic sitesScore 4 or 5 on 5-PS with reduced uptake compared with baseline and residual mass(es) of any sizeAll of the following:≥ 50% decrease in SPD of up to 6 target measureable nodes and extranodal sitesAt interim these findings suggest responding diseaseWhen a lesion is too small to measure on CT, assign 5 mm x 5 mm as the default valueAt end of treatment these findings may indicate residual diseaseWhen no longer visible, 0 mm x 0 mmFor a node > 5 mm x 5 mm, but smaller than normal, use actual measurement for calculationNon-measured lesionN / AAbsent / normal, regressed, but no increaseOrgan enlargementN / ASpleen must have regressed by >50% in length beyond normalNew LesionsNoneNoneBone MarrowResidual uptake higher than uptake in normal marrow but reduced compared with baseline. If persistent focal changes in the marrow in the context of nodal response, consider MRI or biopsy or interval scanN / AStable DiseaseTarget nodes / nodal masses, extranodal lesionsScore 4 or 5 on 5-PS with no significant change in FDG uptake from baseline<50% decrease from baseline of up to 6 dominant, measureable nodes and extranodal sitesNo criteria for progressive disease are metNon-measured lesionN / ANo increase consistent with progressionOrgan enlargementN / ANo increase consistent with progressionNew LesionsNoneNoneBone MarrowNo change from baselineN / AProgressive DiseaseLymph nodes and extralymphatic sitesScore 4 or 5 on 5-PS with an increase in intensity of uptake compared with baseline and / orAt least one of the following:PPD progression:An individual node / lesion must be abnormal with:New FDG-avid foci consistent with lymphomaLDi > 1.5 cm andIncrease by ≥50% from PPD nadir andAn increase in LDi or SDi from nadir0.5 cm for lesions ≤2 cm1.0 cm for lesions > 2 cmIn the setting of splenomegaly, splenic length must increase by >50% of the extent of its prior increase above baseline (eg, a 15 cm spleen must increase to > 16 cm). If no splenomegaly, must increase by at least 2 cm from baseline must increase by at least 2 cm from baselineNew or recurrent splenomegalyNon-measured lesionNoneNew or clear progression of preexisting nonmeasured lesionsNew LesionsNew FDG-avid foci consistent with lymphoma rather than another etiology (eg, infection, inflammation). If uncertain etiology, consider biopsy or interval scanRegrowth of previously resolved lesionsA new node > 1.5 cm in any axisA new extranodal site >1.0 cm in any axis; if <1.0 cm in any axis, its presence must be unequivocal and must be attributable to lymphomaAssessable disease of any size unequivocally attributable to lymphomaBone MarrowNew of recurrent FDG-avid fociNew or recurrent involvement CMR = complete metabolic response; LDi = longest transverse diameter of a lesion; PPD = cross product of the LDi and perpendicular diameter; SDi = shortest axis perpendicular to the LDi; SPD = sum of the product of the perpendicular diameters for multiple lesions; N / A = not applicable. a< Required for CR if bone marrow involvement at baseline b< In Waldeyer's ring or extranodal sites with high physiologic uptake or with activation within spleen or marrow; (eg with chemotherapy or myeloid colony stimulating factors), uptake may be greater than normal mediastinum and / or liver. In this circumstance, CMR may be inferred if uptake at sites of initial involvement is no greater than surrounding normal tissue. c< FDG-avid lymphomas should have response assessed by PET-CT. Some diseases can typically be followed with CT alone (i.e., marginal zone lymphoma). d< PET should be done with contrast-enhanced diagnostic CT and can be done simultaneously or at separate procedures. Table 3. PET Five Point Scale (5-PS). 1No uptake above background2Uptake ≤ mediastinum3Uptake > mediastinum but ≤ liver4Uptake moderately > liver5Uptake markedly higher than liver and / or new lesionsXNew areas of uptake unlikely to be related to lymphoma a< The Deauville five-point scale (5PS) is an internationally recommended scale for clinical routine and clinical trials using FDG-PET / CT in the initial staging and assessment of treatment response in Hodgkin lymphoma (HL) and certain types of non-Hodgkin lymphomas (NHL).

[0061] In one embodiment, the treatment response of CLL / SLL may be assessed by the International Workshop on Chronic Lymphocytic Leukemia criteria (see Hallek, M, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 131(25), 2745-2760 (2018)) (Table 4). Table 4. Response Definition after Treatment for Chronic Lymphocytic Leukemia Patients. Group Parameter CR PR PD SD ALymph nodesNone > 1.5 cmDecrease ≥ 50% (from the baseline) a< Increase ≥ 50% from baseline or from responseChange of - 49% to +49%Liver and / or spleen size b< Spleen size,13 cm; liver size normalDecrease ≥ 50% (from the baseline)Increase ≥ 50% from baseline or from responseChange of - 49% to +49%Constitutional symptomsNoneAnyAnyAnyCirculating lymphocyte countNormalDecrease ≥ 50% from baselineIncrease ≥ 50% over baselineChange of - 49% to +49%BPlatelet count≥ 100 X 10 9< / L≥ 100 X 10 9< / L or increase ≥50% over baselineDecrease of ≥ 50% from baseline secondary to CLLChange of - 49% to +49%Hemoglobin≥ 11.0 g / dL (untransfused and without erythropoietin)≥ 11.0 g / dL or increase ≥ 50% over baselineDecrease of > 2 g / dL from baseline secondary to CLLIncrease, 11.0 g / dL or < 50% over baseline, or decrease < 2 g / dLMarrowNormocellular, no CLL cells, no B-lymphoid nodulesPresence of CLL cells, or of B-lymphoid nodules,or not doneIncrease of CLL cells by ≥ 50% on successive biopsiesNo change in marrow infiltrateCR = complete remission (all of the criteria have to be met); PD = progressive disease (at least 1 of the criteria of group A or group B has to be met); PR = partial remission (for a PR, at least 2 of the parameters of group A and 1 parameter of group B need to improve if previously abnormal; if only 1 parameter of both groups A and B is abnormal before therapy, only 1 needs to improve); SD = stable disease (all of the criteria have to be met; constitutional symptoms alone do not define PD). a< Sum of the products of 6 or fewer lymph nodes (as evaluated by CT scans and physical examination in clinical trials or by physical examination in general practice). b< Spleen size is considered normal if < 13 cm. There is not firmly established international consensus of the size of a normal liver; therefore, liver size should be evaluated by imaging and manual palpation in clinical trials and be recorded according to the definition used in a study protocol.

[0062] In one embodiment, the treatment response of CLL / SLL may be assessed by the Eastern Cooperative Oncology Group (ECOG) performance status (Table 5). Table 5. ECOG Performance Status. Grade ECOG 0Fully active, able to carry on all pre-disease performance without restriction.1Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.2Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.3Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.4Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.5Dead.ECOG = Eastern Cooperative Oncology Group, Robert Comis, MD, Group Chair. Source: Oken M, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5(6):649-655 (1982).

[0063] In certain embodiments, stable disease or lack thereof can be determined by methods known in the art such as evaluation of patient symptoms, physical examination, visualization of the tumor that has been imaged, for example using FDG-PET (fluorodeoxyglucose positron emission tomography), PET / CT (positron emission tomography / computed tomography) scan, MRI (magnetic resonance imaging) of the brain and spine, CSF (cerebrospinal fluid), ophthalmologic exams, vitreal fluid sampling, retinal photograph, bone marrow evaluation and other commonly accepted evaluation modalities.

[0064] As used herein and unless otherwise indicated, the terms "co-administration" and "in combination with" include the administration of one or more therapeutic agents (for example, a compound provided herein and another anti-cancer agent or supportive care agent) either simultaneously, concurrently or sequentially with no specific time limits. In one embodiment, the agents are present in the cell or in the patient's body at the same time or exert their biological or therapeutic effect at the same time. In one embodiment, the therapeutic agents are in the same composition or unit dosage form. In another embodiment, the therapeutic agents are in separate compositions or unit dosage forms.

[0065] The term "supportive care agent" refers to any substance that treats, prevents or manages an adverse effect from treatment with another therapeutic agent.5.2 Compound 1

[0066] Provided for use in the methods provided herein is the compound (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, referred to as "Compound 1": or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. Methods of preparing Compound 1 are described in U.S. Application No. 16 / 390,815. Compound 1, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, is also collectively referred to as "Compound A".

[0067] In one embodiment, Compound 1 free base is used in the methods provided herein. In one embodiment, a pharmaceutically acceptable salt of Compound 1 is used in the methods provided herein. In one embodiment, a hydrochloride salt of Compound 1 is used in the methods provided herein.

[0068] In one embodiment, an enantiomer of Compound 1 (e.g., R-enantiomer of Compound 1) is used in the methods provided herein. In one embodiment, a mixture of enantiomers of Compound 1 (e.g., racemic compound of Compound 1) is used in the methods provided herein.

[0069] In one embodiment, a tautomer of Compound 1 is used in the methods provided herein. In one embodiment, an isotopolog of Compound 1 is used in the methods provided herein.5.3 Second Active Agents

[0070] In one embodiment, the second active agent used in the methods provided herein is a histone deacetylase (HDAC) inhibitor. In one embodiment, the HDAC inhibitor is panobinostat, romidepsin, vorinostat, or citarinostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

[0071] In one embodiment, the HDAC inhibitor is panobinostat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the HDAC inhibitor is panobinostat. In one embodiment, the HDAC inhibitor is a pharmaceutically acceptable salt of panobinostat. In one embodiment, the HDAC inhibitor is panobinostat lactate. In one embodiment, the HDAC inhibitor is a mono-lactate salt of panobinostat. Panobinostat has a chemical name of (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino }methyl)phenyl]acrylamide, and has the structure:

[0072] In one embodiment, the HDAC inhibitor is romidepsin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the HDAC inhibitor is romidepsin. Romidepsin has a chemical name of (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone, and has the structure:

[0073] In one embodiment, the HDAC inhibitor is vorinostat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the HDAC inhibitor is vorinostat. Vorinostat has a chemical name of N-hydroxy-N'-phenyloctanediamide, and has the structure:

[0074] In one embodiment, the HDAC inhibitor is a HDAC6 inhibitor. In one embodiment, the HDAC6 inhibitor is citarinostat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the HDAC6 inhibitor is citarinostat. Citarinostat (also known as ACY-241) has a chemical name of 2-((2-chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide, and has the structure:

[0075] In one embodiment, the second active agent used in the methods provided herein is a B-cell lymphoma 2 (BCL2) inhibitor. In one embodiment, the BCL2 inhibitor is venetoclax, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the BCL2 inhibitor is venetoclax. Venetoclax has a chemical name of 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N({3-nitro-4-[(tetrahydro-2H-pyran-4ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide, and has the structure:

[0076] In one embodiment, the second active agent used in the methods provided herein is a Bruton's tyrosine kinase (BTK) inhibitor. In one embodiment, the BTK inhibitor is ibrutinib, or acalabrutinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

[0077] In one embodiment, the BTK inhibitor is ibrutinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the BTK inhibitor is ibrutinib. Ibrutinib has a chemical name of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1Hpyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one, and has the structure:

[0078] In one embodiment, the BTK inhibitor is acalabrutinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the BTK inhibitor is acalabrutinib. Acalabrutinib has a chemical name of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide, and has the structure:

[0079] In one embodiment, the second active agent used in the methods provided herein is a mammalian target of rapamycin (mTOR) inhibitor. In one embodiment, the mTOR inhibitor is rapamycin or an analog thereof (also termed rapalog). In one embodiment, the mTOR inhibitor is everolimus, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the mTOR inhibitor is everolimus. Everolimus has a chemical name of 40-O-(2-hydroxyethyl)-rapamycin, and has the structure:

[0080] In one embodiment, the second active agent used in the methods provided herein is a phosphoinositide 3-kinase (PI3K) inhibitor. In one embodiment, the PI3K inhibitor is idelalisib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the PI3K inhibitor is idelalisib. Idelalisib has a chemical name of 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6ylamino)propyl]quinazolin-4(3H)-one, and has the structure:

[0081] In one embodiment, the second active agent used in the methods provided herein is a protein kinase C beta (PKCβ or PKC-β) inhibitor. In one embodiment, the PKCβ inhibitor is enzastaurin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the PKCβ inhibitor is enzastaurin. In one embodiment, the PKCβ inhibitor is a pharmaceutically acceptable salt of enzastaurin. In one embodiment, the PKCβ inhibitor is a hydrochloride salt of enzastaurin. In one embodiment, the PKCβ inhibitor is a bis-hydrochloride salt of enzastaurin. Enzastaurin has a chemical name of 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione, and has the structure:

[0082] In one embodiment, the second active agent used in the methods provided herein is a spleen tyrosine kinase (SYK) inhibitor. In one embodiment, the SYK inhibitor is fostamatinib, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the SYK inhibitor is fostamatinib. In one embodiment, the SYK inhibitor is a pharmaceutically acceptable salt of fostamatinib. In one embodiment, the SYK inhibitor is fostamatinib disodium hexahydrate. Fostamatinib (also known as R788) has a chemical name of (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)methyl dihydrogen phosphate, and has the structure:

[0083] In one embodiment, the second active agent used in the methods provided herein is a Janus kinase 2 (JAK2) inhibitor. In one embodiment, the JAK2 inhibitor is fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

[0084] In one embodiment, the JAK2 inhibitor is fedratinib, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the JAK2 inhibitor is fedratinib. Fedratinib has a chemical name of N-tert-butyl-3-[(5-methyl-2- {4-[2-(pyrrolidin-1-yl)ethoxy]anilino}pyrimidin-4-yl)amino]benzenesulfonamide, and has the structure:

[0085] In one embodiment, the JAK2 inhibitor is pacritinib, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the JAK2 inhibitor is pacritinib. Pacritinib has the structure:

[0086] In one embodiment, the JAK2 inhibitor is ruxolitinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the JAK2 inhibitor is ruxolitinib. In one embodiment, the JAK2 inhibitor is a pharmaceutically acceptable salt of ruxolitinib. In one embodiment, the JAK2 inhibitor is ruxolitinib phosphate. Ruxolitinib has a chemical name of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, and has the structure:

[0087] In one embodiment, the second active agent used in the methods provided herein is an Aurora kinase inhibitor. In one embodiment, the Aurora kinase inhibitor is an Aurora kinase A inhibitor. In one embodiment, the Aurora kinase inhibitor is an Aurora kinase B inhibitor. In one embodiment, the Aurora kinase inhibitor is pan-Aurora kinase inhibitor.

[0088] In one embodiment, the Aurora kinase inhibitor is alisertib, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is alisertib. Alisertib has a chemical name of 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-SH-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)-2-methoxybenzoic acid, and has the structure:

[0089] In one embodiment, the Aurora kinase inhibitor is barasertib (also known as AZD1152) or AZD1152-HQPA, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is barasertib. In one embodiment, the Aurora kinase inhibitor is AZD1152-HQPA. AZD1152-HQPA (also known as AZD2811) has a chemical name of 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide, and has the structure:

[0090] Barasertib is a dihydrogen phosphate prodrug of AZD1152-HQPA, and has the structure:

[0091] In one embodiment, the Aurora kinase inhibitor is danusertib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is danusertib. Danusertib (also known as PHA-739358) has the structure:

[0092] In one embodiment, the Aurora kinase inhibitor is AT9283, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is AT9283. AT9283 has the structure:

[0093] In one embodiment, the Aurora kinase inhibitor is PF-03814735, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is PF-03814735. PF-03814735 has the structure:

[0094] In one embodiment, the Aurora kinase inhibitor is AMG900, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is AMG900. AMG900 has the structure:

[0095] In one embodiment, the Aurora kinase inhibitor is tozasertib, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is tozasertib. Tozasertib (also known as VX-680 or MK-0457) has the structure:

[0096] In one embodiment, the Aurora kinase inhibitor is ZM447439, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is ZM447439. ZM447439 has the structure:

[0097] In one embodiment, the Aurora kinase inhibitor is MLN8054, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is MLN8054. MLN8054 has the structure:

[0098] In one embodiment, the Aurora kinase inhibitor is hesperadin, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is hesperadin. In one embodiment, the Aurora kinase inhibitor is a hydrochloride salt of hesperadin. Hesperadin has the structure:

[0099] In one embodiment, the Aurora kinase inhibitor is SNS-314, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is SNS-314. In one embodiment, the Aurora kinase inhibitor is a mesylate salt of SNS-314. SNS-314 has the structure:

[0100] In one embodiment, the Aurora kinase inhibitor is PHA-680632, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is PHA-680632. PHA-680632 has the structure:

[0101] In one embodiment, the Aurora kinase inhibitor is CYC116, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is CYC116. CYC116 has the structure:

[0102] In one embodiment, the Aurora kinase inhibitor is GSK1070916, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is GSK1070916. GSK1070916 has the structure:

[0103] In one embodiment, the Aurora kinase inhibitor is TAK-901, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is TAK-901. TAK-901 has the structure:

[0104] In one embodiment, the Aurora kinase inhibitor is CCT137690, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the Aurora kinase inhibitor is CCT137690. CCT137690 has the structure:

[0105] In one embodiment, the second active agent used in the methods provided herein is an enhancer of zeste homolog 2 (EZH2) inhibitor. In one embodiment, the EZH2 inhibitor is tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A (DZNep), EPZ005687, EI1, UNC1999, or sinefungin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

[0106] In one embodiment, the EZH2 inhibitor is tazemetostat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the EZH2 inhibitor is tazemetostat. Tazemetostat (also known as EPZ-6438) has a chemical name of N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-[1,1'-biphenyl]-3-carboxamide, and has the structure:

[0107] In one embodiment, the EZH2 inhibitor is GSK126, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the EZH2 inhibitor is GSK126 (also known as GSK-2816126). GSK126 has a chemical name of (S)-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide, and has the structure:

[0108] In one embodiment, the EZH2 inhibitor is CPI-1205, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the EZH2 inhibitor is CPI-1205. CPI-1205 has a chemical name of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide, and has the structure:

[0109] In one embodiment, the EZH2 inhibitor is 3-deazaneplanocin A. In one embodiment, the EZH2 inhibitor is EPZ005687. In one embodiment, the EZH2 inhibitor is EI1. In one embodiment, the EZH2 inhibitor is UNC1999. In one embodiment, the EZH2 inhibitor is sinefungin.

[0110] In one embodiment, the second active agent used in the methods provided herein is a bromodomain and extra-terminal motif protein (BET) inhibitor. In one embodiment, the BET inhibitor is birabresib or Compound B, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

[0111] In one embodiment, the BET inhibitor is birabresib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the BET inhibitor is birabresib. Birabresib (also known as OTX015 or MK-8628) has a chemical name of (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide, and has the structure:

[0112] In one embodiment, the BET inhibitor is Compound B, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. Compound B has a chemical name of 4-[2-(cyclopropylmethoxy)-5-(methanesulfonyl)phenyl]-2-methylisoquinolin-1(2H)-one, and has the structure:

[0113] In one embodiment, the BET inhibitor is BMS-986158, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the BET inhibitor is BMS-986158. BMS-986158 has the structure:

[0114] In one embodiment, the BET inhibitor is RO-6870810, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the BET inhibitor is RO-6870810. RO-6870810 has the structure:

[0115] In one embodiment, the BET inhibitor is CPI-0610, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the BET inhibitor is CPI-0610. CPI-0610 has the structure:

[0116] In one embodiment, the BET inhibitor is molibresib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the BET inhibitor is molibresib. Molibresib (also known as GSK-525762) has the structure:

[0117] In one embodiment, the second active agent used in the methods provided herein is a hypomethylating agent. In one embodiment, the hypomethylating agent is a DNA methyltransferase inhibitor. In one embodiment, the hypomethylating agent is 5-azacytidine or decitabine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. Unless otherwise specified, the terms "azacytidine" and "azacitidine" are used interchangeably.

[0118] In one embodiment, the hypomethylating agent is 5-azacytidine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the hypomethylating agent is 5-azacytidine. 5-Azacytidine has a chemical name of 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one, and has the structure:

[0119] In one embodiment, the hypomethylating agent is decitabine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the hypomethylating agent is decitabine. Decitabine has a chemical name of 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one, and has the structure:

[0120] In one embodiment, the second active agent used in the methods provided herein is a disruptor of telomeric silencing 1-like (DOT1L) inhibitor. In one embodiment, the DOT1L inhibitor is pinometostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the DOT1L inhibitor is pinometostat. Pinometostat (also known as EPZ-5676) has a chemical name of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol, and has the structure:

[0121] In one embodiment, the DOT1L inhibitor is SGC0946, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the DOT1L inhibitor is SGC0946. SGC0946 has a chemical name of 5 bromo-7-[5-deoxy-5-[[3-[[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]propyl](1-methylethyl)amino]-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine, and has the structure:

[0122] In one embodiment, the second active agent used in the methods provided herein is a histone acetyltransferase (HAT) inhibitor. In one embodiment, the HAT inhibitor is C646, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the HAT inhibitor is C646. C646 has a chemical name of 4-(4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid, and has the structure:

[0123] In one embodiment, the second active agent used in the methods provided herein is a WD repeat-containing protein 5 (WDR5) inhibitor. In one embodiment, the WDR5 inhibitor is OICR-9429, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the WDR5 inhibitor is OICR-9429. OICR-9429 has a chemical name of N-(4-(4-methylpiperazin-1-yl)-3'-(morpholinomethyl)-[1,1'-biphenyl]-3-yl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide, and has the structure:

[0124] In one embodiment, the second active agent used in the methods provided herein is a DNA (cytosine-5)-methyltransferase 1 (DNMT1) inhibitor. In one embodiment, the DNMT1 inhibitor is a DNMT1 selective inhibitor. In one embodiment, the DNMT1 selective inhibitor is GSK3484862, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the DNMT1 selective inhibitor is GSK3484862. GSK3484862 (also known as GSKMI-714) has a chemical name of (R)-2-((3,5-dicyano-6-(dimethylamino)-4-ethylpyridin-2-yl)thio)-2-phenylacetamide, and has the structure:

[0125] In one embodiment, the second active agent used in the methods provided herein is a lysine-specific demethylase 1 (LSD-1) inhibitor. In one embodiment, the LSD-1 inhibitor is Compound C or seclidemstat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

[0126] In one embodiment, the LSD-1 inhibitor is Compound C, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the LSD-1 inhibitor is Compound C. In one embodiment, the LSD-1 inhibitor is a pharmaceutically acceptable salt of Compound C. In one embodiment, the LSD-1 inhibitor is Compound C besylate. In one embodiment, the LSD-1 inhibitor is Compound C mono-besylate. Compound C has a chemical name of 4-(2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile, and has the structure:

[0127] In one embodiment, the LSD-1 inhibitor is seclidemstat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the LSD-1 inhibitor is seclidemstat. In one embodiment, the LSD-1 inhibitor is a pharmaceutically acceptable salt of seclidemstat. In one embodiment, the LSD-1 inhibitor is seclidemstat mesylate. Seclidemstat (also known as SP-2577) has a chemical name of (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-((4-methylpiperazin-1-yl)sulfonyl)benzohydrazide, and has the structure:

[0128] In one embodiment, the second active agent used in the methods provided herein is a G9A (one of the histone H3 methyltransferases) inhibitor. In one embodiment, the G9A inhibitor is UNC0631, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the G9A inhibitor is UNC0631. UNC0631 has a chemical name of N-(1-(cyclohexylmethyl)piperidin-4-yl)-2-(4-isopropyl-1,4-diazepan-1-yl)-6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-amine, and has the structure:

[0129] In one embodiment, the second active agent used in the methods provided herein is a protein arginine methyltransferase 5 (PRMT5) inhibitor. In one embodiment, the PRMT5 inhibitor is GSK3326595, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the PRMT5 inhibitor is GSK3326595. GSK3326595 (also known as EPZ-015938) has a chemical name of (S)-6-((1-acetylpiperidin-4-yl)amino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide, and has the structure:

[0130] In one embodiment, the second active agent used in the methods provided herein is a bromodomain (BRD) inhibitor. In one embodiment, the BRD inhibitor is a BRD9 / 7 inhibitor. In one embodiment, the BRD9 / 7 inhibitor is LP99, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the BRD9 / 7 inhibitor is LP99. LP99 has a chemical name of N-((2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-7-yl)-6-oxopiperidin-3-yl)-2-methylpropane-1-sulfonamide, and has the structure:

[0131] In one embodiment, the BRD inhibitor is a BRD4 inhibitor. In one embodiment, the BRD4 inhibitor is JQ1, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the BRD4 inhibitor is JQ1. JQ1 has a chemical name of (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate, and has the structure:

[0132] In one embodiment, the second active agent used in the methods provided herein is a SUV420H1 / H2 (two homologous enzymes that methylate lysine 20 of histone H4) inhibitor. In one embodiment, the SUV420H1 / H2 inhibitor is A-196, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the SUV420H1 / H2 inhibitor is A-196. A-196 has a chemical name of 6,7-dichloro-N-cyclopentyl-4-(pyridin-4-yl)phthalazin-1-amine, and has the structure:

[0133] In one embodiment, the second active agent used in the methods provided herein is a coactivator-associated arginine methyltransferase 1 (CARM1) inhibitor. In one embodiment, the CARM1 inhibitor is EZM2302, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the CARM1 inhibitor is EZM2302. EZM2302 has a chemical name of methyl (R)-2-(2-(2-chloro-5-(2-hydroxy-3-(methylamino)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-yl)-2,7-diazaspiro[3.5]nonane-7-carboxylate, and has the structure:

[0134] In one embodiment, the second active agent used in the methods provided herein is a polo-like kinase 1 (PLK1) inhibitor. In one embodiment, the PLK1 inhibitor is BI2536, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the PLK1 inhibitor is BI2536. BI2536 has a chemical name of (R)-4-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide, and has the structure:

[0135] In one embodiment, the PLK1 inhibitor is volasertib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the PLK1 inhibitor is volasertib. Volasertib (also known as BI6727) has the structure:

[0136] In one embodiment, the PLK1 inhibitor is CYC140, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

[0137] In one embodiment, the PLK1 inhibitor is onvansertib, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the PLK1 inhibitor is onvansertib. Onvansertib (also known as NMS-1286937) has the structure:

[0138] In one embodiment, the PLK1 inhibitor is GSK461364, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the PLK1 inhibitor is GSK461364. GSK461364 has the structure:

[0139] In one embodiment, the PLK1 inhibitor is TAK960, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the PLK1 inhibitor is TAK960. In one embodiment, the PLK1 inhibitor is a hydrochloride salt of TAK960. TAK960 has the structure:

[0140] In one embodiment, the second active agent used in the methods provided herein is a serine / threonine-protein kinase (NEK2) inhibitor. In one embodiment, the NEK2 inhibitor is JH295, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the NEK2 inhibitor is JH295. JH295 has a chemical name of (Z)-N-(3-((2-ethyl-4-methyl-1H-imidazol-5-yl)methylene)-2-oxoindolin-5-yl)propiolamide, and has the structure:

[0141] In one embodiment, the NEK2 inhibitor is rac-CCT 250863, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the NEK2 inhibitor is rac-CCT 250863. Rac-CCT 250863 has a chemical name of 4-[2-amino-5-[4-[(dimethylamino)methyl]-2-thienyl]-3-pyridinyl]-2-[[(2Z)-4,4,4-trifluoro-1-methyl-2-buten-1-yl]oxy]benzamide, and has the structure:

[0142] In one embodiment, the second active agent used in the methods provided herein is a mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor. In one embodiment, the MEK inhibitor interrupts the function of the RAF / RAS / MEK signal transduction cascade. In one embodiment, the MEK inhibitor is trametinib, trametinib dimethyl sulfoxide, cobimetinib, binimetinib, or selumetinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the MEK inhibitor is trametinib or trametinib dimethyl sulfoxide, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the MEK inhibitor is trametinib. In one embodiment, the MEK inhibitor is trametinib dimethyl sulfoxide. In one embodiment, the MEK inhibitor is cobimetinib. In one embodiment, the MEK inhibitor is binimetinib. In one embodiment, the MEK inhibitor is selumetinib. Trametinib dimethyl sulfoxide has a chemical name of N-[3-[3-cyclopropyl-5-[(2-fluoro-4- iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl- 2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-acetamide, compound with dimethyl sulfoxide (1:1). Trametinib dimethyl sulfoxide has the structure:

[0143] In one embodiment, the second active agent used in the methods provided herein is a PHD Finger Protein 19 (PHF19) inhibitor.

[0144] In one embodiment, the second active agent used in the methods provided herein is a proviral integration site for Moloney murine leukemia kinase (PIM) inhibitor. In one embodiment, the PIM inhibitor is a pan-PIM inhibitor. In one embodiment, the PIM inhibitor is LGH-447, AZD1208, SGI-1776, or TP-3654, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the PIM inhibitor is LGH-447, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the PIM inhibitor is LGH-447. In one embodiment, the PIM inhibitor is a pharmaceutically acceptable salt of LGH-447. In one embodiment, the PIM inhibitor is a hydrochloride salt of LGH-447. In one embodiment, the hydrochloride salt of LGH-447 is a di-hydrochloride salt. In one embodiment, the hydrochloride salt of LGH-447 is a mono-hydrochloride salt. In one embodiment, the PIM inhibitor is AZD1208. In one embodiment, the PIM inhibitor is SGI-1776. In one embodiment, the PIM inhibitor is TP-3654. LGH-447 has a chemical name of N-[4-[(1R,3S,5S)-3-amino-5-methylcyclohexyl]-3-pyridinyl]-6-(2,6-difluorophenyl)-5-fluoro-2-pyridinecarboxamide, and has the structure:

[0145] In one embodiment, the second active agent used in the methods provided herein is an insulin-like growth factor 1 receptor (IGF-1R) inhibitor. In one embodiment, the IGF-1R inhibitor is linsitinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the IGF-1R inhibitor is linsitinib. Linsitinib has a chemical name of cis-3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol, and has the structure:

[0146] In one embodiment, the second active agent used in the methods provided herein is an exportin 1 (XPO1) inhibitor. In one embodiment, the XPO1 inhibitor is selinexor, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the XPO1 inhibitor is selinexor. Selinexor has a chemical name of (2Z)-3-{3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl}-N'-(pyrazin-2-yl)prop-2-enehydrazide, and has the structure:

[0147] In one embodiment, the second active agent used in the methods provided herein is a survivin (also called baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5) inhibitor. In one embodiment, the BIRC5 inhibitor is YM155, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the BIRC5 inhibitor is YM155. YM155 has a chemical name of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide, and has the structure:

[0148] In one embodiment, the second active agent used in the methods provided herein is a chemotherapy. In one embodiment, the chemotherapy is bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, prodrug, or pharmaceutically acceptable salt thereof.

[0149] In one embodiment, the chemotherapy is bendamustine, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the chemotherapy is bendamustine. In one embodiment, the chemotherapy is a pharmaceutically acceptable salt of bendamustine. In one embodiment, the chemotherapy is bendamustine hydrochloride. In one embodiment, the chemotherapy is a mono-hydrochloride salt of bendamustine. Bendamustine has a chemical name of 4-(5-(bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid, and has the structure:

[0150] In one embodiment, the chemotherapy is doxorubicin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the chemotherapy is doxorubicin. In one embodiment, the chemotherapy is a pharmaceutically acceptable salt of doxorubicin. In one embodiment, the chemotherapy is doxorubicin hydrochloride. In one embodiment, the chemotherapy is a mono-hydrochloride salt of doxorubicin. Doxorubicin has the structure:

[0151] In one embodiment, the chemotherapy is etoposide, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, prodrug, or pharmaceutically acceptable salt thereof. In one embodiment, the chemotherapy is etoposide. Etoposide has a chemical name of 4'-demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-β-D-glucopyranoside], and has the structure:

[0152] In one embodiment, the chemotherapy is a prodrug of etoposide. In one embodiment, the chemotherapy is an ester prodrug of etoposide. In one embodiment, the chemotherapy is etoposide phosphate. Etoposide phosphate has a chemical name of 4'-demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-β-D-glucopyranoside], 4' (dihydrogen phosphate), and has the structure:

[0153] In one embodiment, the chemotherapy is methotrexate, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the chemotherapy is methotrexate. In one embodiment, the chemotherapy is a pharmaceutically acceptable salt of methotrexate. In one embodiment, the chemotherapy is methotrexate sodium. Methotrexate has a chemical name of (4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoyl)-L-glutamic acid, and has the structure:

[0154] In one embodiment, the chemotherapy is cytarabine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the chemotherapy is cytarabine. Cytarabine has a chemical name of 4-amino-1-β-D-arabinofuranosyl-2(1H)pyrimidinone, and has the structure:

[0155] In one embodiment, the chemotherapy is vincristine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the chemotherapy is vincristine. In one embodiment, the chemotherapy is a pharmaceutically acceptable salt of vincristine. In one embodiment, the chemotherapy is vincristine sulfate. In one embodiment, the chemotherapy is a mono-sulfate salt of vincristine. Vincristine has the structure:

[0156] In one embodiment, the chemotherapy is ifosfamide, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the chemotherapy is ifosfamide. Ifosfamide has a chemical name of 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide, and has the structure:

[0157] In one embodiment, the chemotherapy is melphalan, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the chemotherapy is melphalan. In one embodiment, the chemotherapy is a pharmaceutically acceptable salt of melphalan. In one embodiment, the chemotherapy is melphalan hydrochloride. In one embodiment, the chemotherapy is a mono-hydrochloride salt of melphalan. Melphalan has a chemical name of 4-[bis(2-chloroethyl)amino]-L-phenylalanine, and has the structure:

[0158] In one embodiment, the chemotherapy is oxaliplatin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the chemotherapy is oxaliplatin. Oxaliplatin has a chemical name of cis-[(1 R,2 R)-1,2cyclohexanediamine-N,N'] [oxalato(2-)-O,O'] platinum, and has the structure:

[0159] In one embodiment, the chemotherapy is dexamethasone, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, the chemotherapy is dexamethasone. Dexamethasone has a chemical name of (11b,16a)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione, and has the structure: 5.4 Methods of Use

[0160] In one embodiment, provided herein is a method of treating a hematological malignancy, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is one or more of an HDAC inhibitor (e.g., panobinostat, romidepsin, vorinostat, or citarinostat), a BCL2 inhibitor (e.g., venetoclax), a BTK inhibitor (e.g., ibrutinib or acalabrutinib), an mTOR inhibitor (e.g., everolimus), a PI3K inhibitor (e.g., idelalisib), a PKCβ inhibitor (e.g., enzastaurin), a SYK inhibitor (e.g., fostamatinib), a JAK2 inhibitor (e.g., fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib), an Aurora kinase inhibitor (e.g., alisertib), an EZH2 inhibitor (e.g., tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A, EPZ005687, EI1, UNC1999, or sinefungin), a BET inhibitor (e.g., birabresib or Compound B), a hypomethylating agent (e.g., 5-azacytidine or decitabine), a DOT1L inhibitor (e.g., pinometostat), a HAT inhibitor (e.g., C646), a WDR5 inhibitor (e.g., OICR-9429), a DNMT1 inhibitor (e.g., GSK3484862), an LSD-1 inhibitor (e.g., Compound C or seclidemstat), a G9A inhibitor (e.g., UNC 0631), a PRMT5 inhibitor (e.g., GSK3326595), a BRD inhibitor (e.g., LP99), a SUV420H1 / H2 inhibitor (e.g., A-196), a CARM1 inhibitor (e.g., EZM2302), a PLK1 inhibitor (e.g., BI2536), an NEK2 inhibitor (e.g., JH295), an MEK inhibitor (e.g., trametinib), a PHF19 inhibitor, a PIM inhibitor (e.g., LGH-447), an IGF-1R inhibitor (e.g., linsitinib), an XPO1 inhibitor (e.g., selinexor), a BIRC5 inhibitor (e.g., YM155), or a chemotherapy (e.g., bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone). Also provided herein is Compound A for use in a method of treating a hematological malignancy, wherein the method comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent provided herein.

[0161] In one embodiment, provided herein is a method of preventing a hematological malignancy, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is one or more of an HDAC inhibitor (e.g., panobinostat, romidepsin, vorinostat, or citarinostat), a BCL2 inhibitor (e.g., venetoclax), a BTK inhibitor (e.g., ibrutinib or acalabrutinib), an mTOR inhibitor (e.g., everolimus), a PI3K inhibitor (e.g., idelalisib), a PKCβ inhibitor (e.g., enzastaurin), a SYK inhibitor (e.g., fostamatinib), a JAK2 inhibitor (e.g., fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib), an Aurora kinase inhibitor (e.g., alisertib), an EZH2 inhibitor (e.g., tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A, EPZ005687, EI1, UNC1999, or sinefungin), a BET inhibitor (e.g., birabresib or Compound B), a hypomethylating agent (e.g., 5-azacytidine or decitabine), a DOT1L inhibitor (e.g., pinometostat), a HAT inhibitor (e.g., C646), a WDR5 inhibitor (e.g., OICR-9429), a DNMT1 inhibitor (e.g., GSK3484862), an LSD-1 inhibitor (e.g., Compound C or seclidemstat), a G9A inhibitor (e.g., UNC 0631), a PRMT5 inhibitor (e.g., GSK3326595), a BRD inhibitor (e.g., LP99), a SUV420H1 / H2 inhibitor (e.g., A-196), a CARM1 inhibitor (e.g., EZM2302), a PLK1 inhibitor (e.g., BI2536), an NEK2 inhibitor (e.g., JH295), an MEK inhibitor (e.g., trametinib), a PHF19 inhibitor, a PIM inhibitor (e.g., LGH-447), an IGF-1R inhibitor (e.g., linsitinib), an XPO1 inhibitor (e.g., selinexor), a BIRC5 inhibitor (e.g., YM155), or a chemotherapy (e.g., bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone). Also provided herein is Compound A for use in a method of preventing a hematological malignancy, wherein the method comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent provided herein.

[0162] In one embodiment, provided herein is a method of managing a hematological malignancy, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is one or more of an HDAC inhibitor (e.g., panobinostat, romidepsin, vorinostat, or citarinostat), a BCL2 inhibitor (e.g., venetoclax), a BTK inhibitor (e.g., ibrutinib or acalabrutinib), an mTOR inhibitor (e.g., everolimus), a PI3K inhibitor (e.g., idelalisib), a PKCβ inhibitor (e.g., enzastaurin), a SYK inhibitor (e.g., fostamatinib), a JAK2 inhibitor (e.g., fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib), an Aurora kinase inhibitor (e.g., alisertib), an EZH2 inhibitor (e.g., tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A, EPZ005687, EI1, UNC1999, or sinefungin), a BET inhibitor (e.g., birabresib or Compound B), a hypomethylating agent (e.g., 5-azacytidine or decitabine), a DOT1L inhibitor (e.g., pinometostat), a HAT inhibitor (e.g., C646), a WDR5 inhibitor (e.g., OICR-9429), a DNMT1 inhibitor (e.g., GSK3484862), an LSD-1 inhibitor (e.g., Compound C or seclidemstat), a G9A inhibitor (e.g., UNC 0631), a PRMT5 inhibitor (e.g., GSK3326595), a BRD inhibitor (e.g., LP99), a SUV420H1 / H2 inhibitor (e.g., A-196), a CARM1 inhibitor (e.g., EZM2302), a PLK1 inhibitor (e.g., BI2536), an NEK2 inhibitor (e.g., JH295), an MEK inhibitor (e.g., trametinib), a PHF19 inhibitor, a PIM inhibitor (e.g., LGH-447), an IGF-1R inhibitor (e.g., linsitinib), an XPO1 inhibitor (e.g., selinexor), a BIRC5 inhibitor (e.g., YM155), or a chemotherapy (e.g., bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone). Also provided herein is Compound A for use in a method of managing a hematological malignancy, wherein the method comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent provided herein.

[0163] In one embodiment, the hematological malignancy is leukemia.

[0164] In one embodiment, the hematological malignancy is acute myeloid leukemia. In one embodiment, the acute myeloid leukemia is B-cell acute myeloid leukemia.

[0165] In one embodiment, the hematological malignancy is acute lymphocytic leukemia.

[0166] In one embodiment, the hematological malignancy is chronic lymphocytic leukemia / small lymphocytic lymphoma.

[0167] In one embodiment, the hematological malignancy is myeloma.

[0168] In one embodiment, the hematological malignancy is multiple myeloma. In one embodiment, the multiple myeloma is plasma cell leukemia (PCL).

[0169] In one embodiment, the hematological malignancy is lymphoma.

[0170] In one embodiment, the hematological malignancy is non-Hodgkin's lymphoma.

[0171] In one embodiment, the hematological malignancy is diffuse large B-cell lymphoma.

[0172] In one embodiment, the hematological malignancy is T-cell lymphoma. In one embodiment, the T-cell lymphoma is anaplastic large cell lymphoma (ALCL). In one embodiment, the T-cell lymphoma is Sezary Syndrome.

[0173] In one embodiment, the hematological malignancy is Burkitt lymphoma.

[0174] In one embodiment, the hematological malignancy is marginal zone lymphoma. In one embodiment, the marginal zone lymphoma is splenic marginal zone lymphoma (SMZL).

[0175] In one embodiment, the hematological malignancy is Hodgkin's lymphoma.

[0176] In one embodiment, the hematological malignancy is myelodysplastic syndromes.

[0177] In one embodiment, the DLBCL is activated B-cell-like DLBCL (ABC-DLBCL). In one embodiment, the DLBCL is germinal center B-cell-like DLBCL (GCB-DLBCL). In one embodiment, the DLBCL is unclassified DLBCL. In one embodiment, the DLBCL is primary mediastinal B-cell type DLBCL (PMBL DLBCL). In one embodiment, the DLBCL is double-hit DLBCL (DHIT DLBCL), also referred to as cMyc / Bcl-2 mutant DLBCL. In one embodiment, the DLBCL is triple-hit DLBCL (THIT DLBCL) also referred to as cMyc / Bcl2 / Bcl6 rearrangement DLBCL.

[0178] In one embodiment, the DLBCL is newly diagnosed DLBCL. In one embodiment, the DLBCL is primary DLBCL. In one embodiment, the DLBCL is relapsed DLBCL. In one embodiment, the DLBCL is refractory DLBCL. In one embodiment, the DLBCL is relapsed or refractory DLBCL. In one embodiment, the DLBCL is relapsed / refractory DLBCL. In one embodiment, the DLBCL is refractory to doxorubicin. In one embodiment, the DLBCL is resistant to doxorubicin. In one embodiment, the DLBCL is refractory to one or more of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide, bendamustine, lenalidomide, gemcitabine, dexamethasone, ifosfamide, polatuxuab, or CAR-T.

[0179] In one embodiment, the DLBCL is treated with two or more prior lines of treatment.

[0180] In one embodiment, the DLBCL is transformed lymphoma. In another embodiment, the DLBCL is not otherwise specified (NOS) DLBCL.

[0181] As used herein and unless otherwise indicated, "CLL / SLL" or "CLL and / or SLL" means CLL, or SLL, or CLL and SLL. In one embodiment, the methods provided herein are for treating, preventing or managing CLL. In one embodiment, the methods provided herein are for treating, preventing or managing SLL. In one embodiment, the methods provided herein are for treating, preventing or managing CLL and CLL.

[0182] In one embodiment, the CLL / SLL subject has failed one or more lines of therapy. In one embodiment, the subject has failed at least one prior therapy. In one embodiment, the subject has failed at least two prior therapies. In one embodiment, the subject has been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor. In one embodiment, the subject is relapsed or refractory to a BTK inhibitor. In one embodiment, the BTK inhibitor is ibrutinib. In one embodiment, the BTK inhibitor is acalabrutinib. In one embodiment, the BTK inhibitor is zanubrutinib. In one embodiment, the BTK inhibitor is tirabrutinib.

[0183] In one embodiment, the CLL / SLL is newly diagnosed CLL / SLL. In one embodiment, the CLL / SLL is relapsed or refractory CLL / SLL (R / R CLL / SLL).

[0184] In one embodiment, the CLL is characterized by mutated IGHV (Immunoglobulin Heavy Chain Gene). In one embodiment, the CLL is characterized by non-mutated IGHV.

[0185] In one embodiment, the CLL is characterized by one or more mutations in TP53 (Tumor Protein 53). In one embodiment, the CLL is characterized by wild type TP53.

[0186] In one embodiment, the CLL is characterized by one or more cytogenetic abnormalities, e.g., del(13q), del(11q), del(17p), tri12, t(6;17), del(11q22.3), t(11;14), del(18q), and t(14;19). In one embodiment, the CLL is characterized by del(17p).

[0187] In one embodiment, the CLL is characterized by Richter's Transformation (also known as Richter's Syndrome).

[0188] In one embodiment, the hematological malignancy is newly diagnosed. In one embodiment, the hematological malignancy is relapsed or refractory.

[0189] In one embodiment, the AML is newly diagnosed AML. In one embodiment, the AML is relapsed or refractory AML. In one embodiment, the B-cell AML is newly diagnosed B-cell AML. In one embodiment, the B-cell AML is relapsed or refractory B-cell AML.

[0190] In one embodiment, the ALL is newly diagnosed ALL. In one embodiment, the ALL is relapsed or refractory ALL.

[0191] In one embodiment, the MM is newly diagnosed MM. In one embodiment, the MM is relapsed or refractory MM. In one embodiment, the PCL is newly diagnosed PCL. In one embodiment, the PCL is relapsed or refractory PCL.

[0192] In one embodiment, the HL is newly diagnosed HL. In one embodiment, the HL is relapsed or refractory HL.

[0193] In one embodiment, the NHL is newly diagnosed NHL. In one embodiment, the NHL is relapsed or refractory NHL.

[0194] In one embodiment, the TCL is newly diagnosed TCL. In one embodiment, the TCL is relapsed or refractory TCL. In one embodiment, the ALCL is newly diagnosed ALCL. In one embodiment, the ALCL is relapsed or refractory ALCL. In one embodiment, the Sezary Syndrome is newly diagnosed Sezary Syndrome. In one embodiment, the Sezary Syndrome is relapsed or refractory Sezary Syndrome.

[0195] In one embodiment, the BL is newly diagnosed BL. In one embodiment, the BL is relapsed or refractory BL.

[0196] In one embodiment, the MZL is newly diagnosed MZL. In one embodiment, the MZL is relapsed or refractory MZL. In one embodiment, the SMZL is newly diagnosed SMZL. In one embodiment, the SMZL is relapsed or refractory SMZL.

[0197] In one embodiment, the MDS is newly diagnosed MDS. In one embodiment, the MDS is relapsed or refractory MDS.

[0198] In one embodiment, provided herein are methods for achieving a complete response, partial response, or stable disease in a patient, comprising administering to a patient having a hematological malignancy provided herein a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is one or more of an HDAC inhibitor (e.g., panobinostat, romidepsin, vorinostat, or citarinostat), a BCL2 inhibitor (e.g., venetoclax), a BTK inhibitor (e.g., ibrutinib or acalabrutinib), an mTOR inhibitor (e.g., everolimus), a PI3K inhibitor (e.g., idelalisib), a PKCβ inhibitor (e.g., enzastaurin), a SYK inhibitor (e.g., fostamatinib), a JAK2 inhibitor (e.g., fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib), an Aurora kinase inhibitor (e.g., alisertib), an EZH2 inhibitor (e.g., tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A, EPZ005687, EI1, UNC1999, or sinefungin), a BET inhibitor (e.g., birabresib or Compound B), a hypomethylating agent (e.g., 5-azacytidine or decitabine), a DOT1L inhibitor (e.g., pinometostat), a HAT inhibitor (e.g., C646), a WDR5 inhibitor (e.g., OICR-9429), a DNMT1 inhibitor (e.g., GSK3484862), an LSD-1 inhibitor (e.g., Compound C or seclidemstat), a G9A inhibitor (e.g., UNC 0631), a PRMT5 inhibitor (e.g., GSK3326595), a BRD inhibitor (e.g., LP99), a SUV420H1 / H2 inhibitor (e.g., A-196), a CARM1 inhibitor (e.g., EZM2302), a PLK1 inhibitor (e.g., BI2536), an NEK2 inhibitor (e.g., JH295), an MEK inhibitor (e.g., trametinib), a PHF19 inhibitor, a PIM inhibitor (e.g., LGH-447), an IGF-1R inhibitor (e.g., linsitinib), an XPO1 inhibitor (e.g., selinexor), a BIRC5 inhibitor (e.g., YM155), or a chemotherapy (e.g., bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone). In one embodiment, the hematological malignancy is AML (e.g., B-cell AML). In one embodiment, the hematological malignancy is ALL. In one embodiment, the hematological malignancy is CLL / SLL. In one embodiment, the hematological malignancy is MM. In one embodiment, the hematological malignancy is PCL. In one embodiment, the hematological malignancy is NHL. In one embodiment, the hematological malignancy is DLBCL. In one embodiment, the hematological malignancy is TCL (e.g., ALCL or Sezary Syndrome). In one embodiment, the hematological malignancy is Burkitt lymphoma. In one embodiment, the hematological malignancy is HL. In one embodiment, the hematological malignancy is MZL (e.g., SMZL). In one embodiment, the hematological malignancy is MDS.

[0199] In one embodiment, provided herein are methods for achieving a complete response, partial response, or stable disease, as determined by the Lugano response criteria in a patient, comprising administering to a patient having DLBCL a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is one or more of an HDAC inhibitor (e.g., panobinostat, romidepsin, vorinostat, or citarinostat), a BCL2 inhibitor (e.g., venetoclax), a BTK inhibitor (e.g., ibrutinib or acalabrutinib), an mTOR inhibitor (e.g., everolimus), a PI3K inhibitor (e.g., idelalisib), a PKCβ inhibitor (e.g., enzastaurin), a SYK inhibitor (e.g., fostamatinib), a JAK2 inhibitor (e.g., fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib), an Aurora kinase inhibitor (e.g., alisertib), an EZH2 inhibitor (e.g., tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A, EPZ005687, EI1, UNC1999, or sinefungin), a BET inhibitor (e.g., birabresib or Compound B), a hypomethylating agent (e.g., 5-azacytidine or decitabine), a DOT1L inhibitor (e.g., pinometostat), a HAT inhibitor (e.g., C646), a WDR5 inhibitor (e.g., OICR-9429), a DNMT1 inhibitor (e.g., GSK3484862), an LSD-1 inhibitor (e.g., Compound C or seclidemstat), a G9A inhibitor (e.g., UNC 0631), a PRMT5 inhibitor (e.g., GSK3326595), a BRD inhibitor (e.g., LP99), a SUV420H1 / H2 inhibitor (e.g., A-196), a CARM1 inhibitor (e.g., EZM2302), a PLK1 inhibitor (e.g., BI2536), an NEK2 inhibitor (e.g., JH295), an MEK inhibitor (e.g., trametinib), a PHF19 inhibitor, a PIM inhibitor (e.g., LGH-447), an IGF-1R inhibitor (e.g., linsitinib), an XPO1 inhibitor (e.g., selinexor), a BIRC5 inhibitor (e.g., YM155), or a chemotherapy (e.g., bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone).

[0200] In one embodiment, provided herein are methods for achieving a complete response, partial response, or stable disease, as determined by the International Workshop on Chronic Lymphocytic Leukemia criteria in a patient, comprising administering to patient having CLL / SLL a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is one or more of an HDAC inhibitor (e.g., panobinostat, romidepsin, vorinostat, or citarinostat), a BCL2 inhibitor (e.g., venetoclax), a BTK inhibitor (e.g., ibrutinib or acalabrutinib), an mTOR inhibitor (e.g., everolimus), a PI3K inhibitor (e.g., idelalisib), a PKCβ inhibitor (e.g., enzastaurin), a SYK inhibitor (e.g., fostamatinib), a JAK2 inhibitor (e.g., fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib), an Aurora kinase inhibitor (e.g., alisertib), an EZH2 inhibitor (e.g., tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A, EPZ005687, EI1, UNC1999, or sinefungin), a BET inhibitor (e.g., birabresib or Compound B), a hypomethylating agent (e.g., 5-azacytidine or decitabine), a DOT1L inhibitor (e.g., pinometostat), a HAT inhibitor (e.g., C646), a WDR5 inhibitor (e.g., OICR-9429), a DNMT1 inhibitor (e.g., GSK3484862), an LSD-1 inhibitor (e.g., Compound C or seclidemstat), a G9A inhibitor (e.g., UNC 0631), a PRMT5 inhibitor (e.g., GSK3326595), a BRD inhibitor (e.g., LP99), a SUV420H1 / H2 inhibitor (e.g., A-196), a CARM1 inhibitor (e.g., EZM2302), a PLK1 inhibitor (e.g., BI2536), an NEK2 inhibitor (e.g., JH295), an MEK inhibitor (e.g., trametinib), a PHF19 inhibitor, a PIM inhibitor (e.g., LGH-447), an IGF-1R inhibitor (e.g., linsitinib), an XPO1 inhibitor (e.g., selinexor), a BIRC5 inhibitor (e.g., YM155), or a chemotherapy (e.g., bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone). In one embodiment, minimal residual disease (MRD) detection may be performed in subjects who undergo bone marrow evaluation for confirmation of a complete response (CR). In one embodiment, provided herein are methods for achieving minimal residual disease (MRD) negativity in a patient, comprising administering to patient having CLL / SLL a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is one or more of an HDAC inhibitor (e.g., panobinostat, romidepsin, vorinostat, or citarinostat), a BCL2 inhibitor (e.g., venetoclax), a BTK inhibitor (e.g., ibrutinib or acalabrutinib), an mTOR inhibitor (e.g., everolimus), a PI3K inhibitor (e.g., idelalisib), a PKCβ inhibitor (e.g., enzastaurin), a SYK inhibitor (e.g., fostamatinib), a JAK2 inhibitor (e.g., fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib), an Aurora kinase inhibitor (e.g., alisertib), an EZH2 inhibitor (e.g., tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A, EPZ005687, EI1, UNC1999, or sinefungin), a BET inhibitor (e.g., birabresib or Compound B), a hypomethylating agent (e.g., 5-azacytidine or decitabine), a DOT1L inhibitor (e.g., pinometostat), a HAT inhibitor (e.g., C646), a WDR5 inhibitor (e.g., OICR-9429), a DNMT1 inhibitor (e.g., GSK3484862), an LSD-1 inhibitor (e.g., Compound C or seclidemstat), a G9A inhibitor (e.g., UNC 0631), a PRMT5 inhibitor (e.g., GSK3326595), a BRD inhibitor (e.g., LP99), a SUV420H1 / H2 inhibitor (e.g., A-196), a CARM1 inhibitor (e.g., EZM2302), a PLK1 inhibitor (e.g., BI2536), an NEK2 inhibitor (e.g., JH295), an MEK inhibitor (e.g., trametinib), a PHF19 inhibitor, a PIM inhibitor (e.g., LGH-447), an IGF-1R inhibitor (e.g., linsitinib), an XPO1 inhibitor (e.g., selinexor), a BIRC5 inhibitor (e.g., YM155), or a chemotherapy (e.g., bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone). In one embodiment, the MRD negativity is measured in peripheral blood and / or bone marrow. In one embodiment, the MRD negativity lasts for a minimum of 3 months.

[0201] In one embodiment, provided herein are methods for achieving an increase in overall survival, progression-free survival, event-free survival, time to progression, or disease-free survival in a patient, comprising administering to a patient having a hematological malignancy provided herein a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is one or more of an HDAC inhibitor (e.g., panobinostat, romidepsin, vorinostat, or citarinostat), a BCL2 inhibitor (e.g., venetoclax), a BTK inhibitor (e.g., ibrutinib or acalabrutinib), an mTOR inhibitor (e.g., everolimus), a PI3K inhibitor (e.g., idelalisib), a PKCβ inhibitor (e.g., enzastaurin), a SYK inhibitor (e.g., fostamatinib), a JAK2 inhibitor (e.g., fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib), an Aurora kinase inhibitor (e.g., alisertib), an EZH2 inhibitor (e.g., tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A, EPZ005687, EI1, UNC1999, or sinefungin), a BET inhibitor (e.g., birabresib or Compound B), a hypomethylating agent (e.g., 5-azacytidine or decitabine), a DOT1L inhibitor (e.g., pinometostat), a HAT inhibitor (e.g., C646), a WDR5 inhibitor (e.g., OICR-9429), a DNMT1 inhibitor (e.g., GSK3484862), an LSD-1 inhibitor (e.g., Compound C or seclidemstat), a G9A inhibitor (e.g., UNC 0631), a PRMT5 inhibitor (e.g., GSK3326595), a BRD inhibitor (e.g., LP99), a SUV420H1 / H2 inhibitor (e.g., A-196), a CARM1 inhibitor (e.g., EZM2302), a PLK1 inhibitor (e.g., BI2536), an NEK2 inhibitor (e.g., JH295), an MEK inhibitor (e.g., trametinib), a PHF19 inhibitor, a PIM inhibitor (e.g., LGH-447), an IGF-1R inhibitor (e.g., linsitinib), an XPO1 inhibitor (e.g., selinexor), a BIRC5 inhibitor (e.g., YM155), or a chemotherapy (e.g., bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone). In one embodiment, the hematological malignancy is AML (e.g., B-cell AML). In one embodiment, the hematological malignancy is ALL. In one embodiment, the hematological malignancy is CLL / SLL. In one embodiment, the hematological malignancy is MM. In one embodiment, the hematological malignancy is PCL. In one embodiment, the hematological malignancy is NHL. In one embodiment, the hematological malignancy is DLBCL. In one embodiment, the hematological malignancy is TCL (e.g., ALCL or Sezary Syndrome). In one embodiment, the hematological malignancy is Burkitt lymphoma. In one embodiment, the hematological malignancy is HL. In one embodiment, the hematological malignancy is MZL (e.g., SMZL). In one embodiment, the hematological malignancy is MDS.

[0202] In one embodiment, provided herein are methods for achieving an increase in overall survival in a patient, comprising administering to a patient having a hematological malignancy provided herein a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is one or more of an HDAC inhibitor (e.g., panobinostat, romidepsin, vorinostat, or citarinostat), a BCL2 inhibitor (e.g., venetoclax), a BTK inhibitor (e.g., ibrutinib or acalabrutinib), an mTOR inhibitor (e.g., everolimus), a PI3K inhibitor (e.g., idelalisib), a PKCβ inhibitor (e.g., enzastaurin), a SYK inhibitor (e.g., fostamatinib), a JAK2 inhibitor (e.g., fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib), an Aurora kinase inhibitor (e.g., alisertib), an EZH2 inhibitor (e.g., tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A, EPZ005687, EI1, UNC1999, or sinefungin), a BET inhibitor (e.g., birabresib or Compound B), a hypomethylating agent (e.g., 5-azacytidine or decitabine), a DOT1L inhibitor (e.g., pinometostat), a HAT inhibitor (e.g., C646), a WDR5 inhibitor (e.g., OICR-9429), a DNMT1 inhibitor (e.g., GSK3484862), an LSD-1 inhibitor (e.g., Compound C or seclidemstat), a G9A inhibitor (e.g., UNC 0631), a PRMT5 inhibitor (e.g., GSK3326595), a BRD inhibitor (e.g., LP99), a SUV420H1 / H2 inhibitor (e.g., A-196), a CARM1 inhibitor (e.g., EZM2302), a PLK1 inhibitor (e.g., BI2536), an NEK2 inhibitor (e.g., JH295), an MEK inhibitor (e.g., trametinib), a PHF19 inhibitor, a PIM inhibitor (e.g., LGH-447), an IGF-1R inhibitor (e.g., linsitinib), an XPO1 inhibitor (e.g., selinexor), a BIRC5 inhibitor (e.g., YM155), or a chemotherapy (e.g., bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone). In one embodiment, the hematological malignancy is AML (e.g., B-cell AML). In one embodiment, the hematological malignancy is ALL. In one embodiment, the hematological malignancy is CLL / SLL. In one embodiment, the hematological malignancy is MM. In one embodiment, the hematological malignancy is PCL. In one embodiment, the hematological malignancy is NHL. In one embodiment, the hematological malignancy is DLBCL. In one embodiment, the hematological malignancy is TCL (e.g., ALCL or Sezary Syndrome). In one embodiment, the hematological malignancy is Burkitt lymphoma. In one embodiment, the hematological malignancy is HL. In one embodiment, the hematological malignancy is MZL (e.g., SMZL). In one embodiment, the hematological malignancy is MDS.

[0203] In one embodiment, provided herein are methods for achieving an increase in progression-free survival in a patient, comprising administering to a patient having a hematological malignancy provided herein a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is one or more of an HDAC inhibitor (e.g., panobinostat, romidepsin, vorinostat, or citarinostat), a BCL2 inhibitor (e.g., venetoclax), a BTK inhibitor (e.g., ibrutinib or acalabrutinib), an mTOR inhibitor (e.g., everolimus), a PI3K inhibitor (e.g., idelalisib), a PKCβ inhibitor (e.g., enzastaurin), a SYK inhibitor (e.g., fostamatinib), a JAK2 inhibitor (e.g., fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib), an Aurora kinase inhibitor (e.g., alisertib), an EZH2 inhibitor (e.g., tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A, EPZ005687, EI1, UNC1999, or sinefungin), a BET inhibitor (e.g., birabresib or Compound B), a hypomethylating agent (e.g., 5-azacytidine or decitabine), a DOT1L inhibitor (e.g., pinometostat), a HAT inhibitor (e.g., C646), a WDR5 inhibitor (e.g., OICR-9429), a DNMT1 inhibitor (e.g., GSK3484862), an LSD-1 inhibitor (e.g., Compound C or seclidemstat), a G9A inhibitor (e.g., UNC 0631), a PRMT5 inhibitor (e.g., GSK3326595), a BRD inhibitor (e.g., LP99), a SUV420H1 / H2 inhibitor (e.g., A-196), a CARM1 inhibitor (e.g., EZM2302), a PLK1 inhibitor (e.g., BI2536), an NEK2 inhibitor (e.g., JH295), an MEK inhibitor (e.g., trametinib), a PHF 19 inhibitor, a PIM inhibitor (e.g., LGH-447), an IGF-1R inhibitor (e.g., linsitinib), an XPO1 inhibitor (e.g., selinexor), a BIRC5 inhibitor (e.g., YM155), or a chemotherapy (e.g., bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone). In one embodiment, the hematological malignancy is AML (e.g., B-cell AML). In one embodiment, the hematological malignancy is ALL. In one embodiment, the hematological malignancy is CLL / SLL. In one embodiment, the hematological malignancy is MM. In one embodiment, the hematological malignancy is PCL. In one embodiment, the hematological malignancy is NHL. In one embodiment, the hematological malignancy is DLBCL. In one embodiment, the hematological malignancy is TCL (e.g., ALCL or Sezary Syndrome). In one embodiment, the hematological malignancy is Burkitt lymphoma. In one embodiment, the hematological malignancy is HL. In one embodiment, the hematological malignancy is MZL (e.g., SMZL). In one embodiment, the hematological malignancy is MDS.

[0204] In one embodiment, provided herein are methods for achieving an increase in event-free survival in a patient, comprising administering to a patient having a hematological malignancy provided herein a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is one or more of an HDAC inhibitor (e.g., panobinostat, romidepsin, vorinostat, or citarinostat), a BCL2 inhibitor (e.g., venetoclax), a BTK inhibitor (e.g., ibrutinib or acalabrutinib), an mTOR inhibitor (e.g., everolimus), a PI3K inhibitor (e.g., idelalisib), a PKCβ inhibitor (e.g., enzastaurin), a SYK inhibitor (e.g., fostamatinib), a JAK2 inhibitor (e.g., fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib), an Aurora kinase inhibitor (e.g., alisertib), an EZH2 inhibitor (e.g., tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A, EPZ005687, EI1, UNC1999, or sinefungin), a BET inhibitor (e.g., birabresib or Compound B), a hypomethylating agent (e.g., 5-azacytidine or decitabine), a DOT1L inhibitor (e.g., pinometostat), a HAT inhibitor (e.g., C646), a WDR5 inhibitor (e.g., OICR-9429), a DNMT1 inhibitor (e.g., GSK3484862), an LSD-1 inhibitor (e.g., Compound C or seclidemstat), a G9A inhibitor (e.g., UNC 0631), a PRMT5 inhibitor (e.g., GSK3326595), a BRD inhibitor (e.g., LP99), a SUV420H1 / H2 inhibitor (e.g., A-196), a CARM1 inhibitor (e.g., EZM2302), a PLK1 inhibitor (e.g., BI2536), an NEK2 inhibitor (e.g., JH295), an MEK inhibitor (e.g., trametinib), a PHF19 inhibitor, a PIM inhibitor (e.g., LGH-447), an IGF-1R inhibitor (e.g., linsitinib), an XPO1 inhibitor (e.g., selinexor), a BIRC5 inhibitor (e.g., YM155), or a chemotherapy (e.g., bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone). In one embodiment, the hematological malignancy is AML (e.g., B-cell AML). In one embodiment, the hematological malignancy is ALL. In one embodiment, the hematological malignancy is CLL / SLL. In one embodiment, the hematological malignancy is MM. In one embodiment, the hematological malignancy is PCL. In one embodiment, the hematological malignancy is NHL. In one embodiment, the hematological malignancy is DLBCL. In one embodiment, the hematological malignancy is TCL (e.g., ALCL or Sezary Syndrome). In one embodiment, the hematological malignancy is Burkitt lymphoma. In one embodiment, the hematological malignancy is HL. In one embodiment, the hematological malignancy is MZL (e.g., SMZL). In one embodiment, the hematological malignancy is MDS.

[0205] In one embodiment, provided herein are methods for achieving an increase in time to progression in a patient, comprising administering to a patient having a hematological malignancy provided herein a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is one or more of an HDAC inhibitor (e.g., panobinostat, romidepsin, vorinostat, or citarinostat), a BCL2 inhibitor (e.g., venetoclax), a BTK inhibitor (e.g., ibrutinib or acalabrutinib), an mTOR inhibitor (e.g., everolimus), a PI3K inhibitor (e.g., idelalisib), a PKCβ inhibitor (e.g., enzastaurin), a SYK inhibitor (e.g., fostamatinib), a JAK2 inhibitor (e.g., fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib), an Aurora kinase inhibitor (e.g., alisertib), an EZH2 inhibitor (e.g., tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A, EPZ005687, EI1, UNC1999, or sinefungin), a BET inhibitor (e.g., birabresib or Compound B), a hypomethylating agent (e.g., 5-azacytidine or decitabine), a DOT1L inhibitor (e.g., pinometostat), a HAT inhibitor (e.g., C646), a WDR5 inhibitor (e.g., OICR-9429), a DNMT1 inhibitor (e.g., GSK3484862), an LSD-1 inhibitor (e.g., Compound C or seclidemstat), a G9A inhibitor (e.g., UNC 0631), a PRMT5 inhibitor (e.g., GSK3326595), a BRD inhibitor (e.g., LP99), a SUV420H1 / H2 inhibitor (e.g., A-196), a CARM1 inhibitor (e.g., EZM2302), a PLK1 inhibitor (e.g., BI2536), an NEK2 inhibitor (e.g., JH295), an MEK inhibitor (e.g., trametinib), a PHF19 inhibitor, a PIM inhibitor (e.g., LGH-447), an IGF-1R inhibitor (e.g., linsitinib), an XPO1 inhibitor (e.g., selinexor), a BIRC5 inhibitor (e.g., YM155), or a chemotherapy (e.g., bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone). In one embodiment, the hematological malignancy is AML (e.g., B-cell AML). In one embodiment, the hematological malignancy is ALL. In one embodiment, the hematological malignancy is CLL / SLL. In one embodiment, the hematological malignancy is MM. In one embodiment, the hematological malignancy is PCL. In one embodiment, the hematological malignancy is NHL. In one embodiment, the hematological malignancy is DLBCL. In one embodiment, the hematological malignancy is TCL (e.g., ALCL or Sezary Syndrome). In one embodiment, the hematological malignancy is Burkitt lymphoma. In one embodiment, the hematological malignancy is HL. In one embodiment, the hematological malignancy is MZL (e.g., SMZL). In one embodiment, the hematological malignancy is MDS.

[0206] In one embodiment, provided herein are methods for achieving an increase in disease-free survival in a patient, comprising administering to a patient having a hematological malignancy provided herein a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is one or more of an HDAC inhibitor (e.g., panobinostat, romidepsin, vorinostat, or citarinostat), a BCL2 inhibitor (e.g., venetoclax), a BTK inhibitor (e.g., ibrutinib or acalabrutinib), an mTOR inhibitor (e.g., everolimus), a PI3K inhibitor (e.g., idelalisib), a PKCβ inhibitor (e.g., enzastaurin), a SYK inhibitor (e.g., fostamatinib), a JAK2 inhibitor (e.g., fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib), an Aurora kinase inhibitor (e.g., alisertib), an EZH2 inhibitor (e.g., tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A, EPZ005687, EI1, UNC1999, or sinefungin), a BET inhibitor (e.g., birabresib or Compound B), a hypomethylating agent (e.g., 5-azacytidine or decitabine), a DOT1L inhibitor (e.g., pinometostat), a HAT inhibitor (e.g., C646), a WDR5 inhibitor (e.g., OICR-9429), a DNMT1 inhibitor (e.g., GSK3484862), an LSD-1 inhibitor (e.g., Compound C or seclidemstat), a G9A inhibitor (e.g., UNC 0631), a PRMT5 inhibitor (e.g., GSK3326595), a BRD inhibitor (e.g., LP99), a SUV420H1 / H2 inhibitor (e.g., A-196), a CARM1 inhibitor (e.g., EZM2302), a PLK1 inhibitor (e.g., BI2536), an NEK2 inhibitor (e.g., JH295), an MEK inhibitor (e.g., trametinib), a PHF19 inhibitor, a PIM inhibitor (e.g., LGH-447), an IGF-1R inhibitor (e.g., linsitinib), an XPO1 inhibitor (e.g., selinexor), a BIRC5 inhibitor (e.g., YM155), or a chemotherapy (e.g., bendamustine, doxorubicin, etoposide, methotrexate, cytarabine, vincristine, ifosfamide, melphalan, oxaliplatin, or dexamethasone). In one embodiment, the hematological malignancy is AML (e.g., B-cell AML). In one embodiment, the hematological malignancy is ALL. In one embodiment, the hematological malignancy is CLL / SLL. In one embodiment, the hematological malignancy is MM. In one embodiment, the hematological malignancy is PCL. In one embodiment, the hematological malignancy is NHL. In one embodiment, the hematological malignancy is DLBCL. In one embodiment, the hematological malignancy is TCL (e.g., ALCL or Sezary Syndrome). In one embodiment, the hematological malignancy is Burkitt lymphoma. In one embodiment, the hematological malignancy is HL. In one embodiment, the hematological malignancy is MZL (e.g., SMZL). In one embodiment, the hematological malignancy is MDS.

[0207] In one embodiment, a method provided herein further comprises administering to the patient a therapeutically effective amount of obinutuzumab. In one embodiment, provided herein is a method of treating a hematological malignancy provided herein, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent provided herein (e.g., venetoclax), and further in combination with obinutuzumab.

[0208] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is panobinostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is panobinostat. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is panobinostat lactate.

[0209] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is romidepsin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is romidepsin.

[0210] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is vorinostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is vorinostat.

[0211] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is citarinostat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is citarinostat.

[0212] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is venetoclax, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is venetoclax.

[0213] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is ibrutinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ibrutinib.

[0214] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is everolimus, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is everolimus.

[0215] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1A, in combination with a second active agent, wherein the second active agent is idelalisib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is idelalisib.

[0216] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is enzastaurin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is enzastaurin. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is a hydrochloride salt of enzastaurin.

[0217] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is fostamatinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fostamatinib. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fostamatinib disodium hexahydrate.

[0218] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is fedratinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fedratinib.

[0219] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is pacritinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is pacritinib.

[0220] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is ruxolitinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ruxolitinib. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ruxolitinib phosphate.

[0221] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is alisertib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is alisertib.

[0222] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is tazemetostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is tazemetostat.

[0223] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK126, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK126.

[0224] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is CPI-1205, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is CPI-1205.

[0225] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is birabresib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is birabresib.

[0226] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is Compound B, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound B.

[0227] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is 5-azacytidine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is 5-azacytidine.

[0228] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is decitabine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is decitabine.

[0229] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is pinometostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is pinometostat.

[0230] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is C646, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is C646.

[0231] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is OICR-9429, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is OICR-9429.

[0232] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK3484862, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK3484862.

[0233] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is Compound C, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound C. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound C besylate.

[0234] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is seclidemstat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is seclidemstat. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is seclidemstat mesylate.

[0235] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is UNC0631, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is UNC0631.

[0236] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK3326595, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK3326595.

[0237] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is LP99, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is LP99.

[0238] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is A-196, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is A-196.

[0239] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is EZM2302, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is EZM2302.

[0240] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is bendamustine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is bendamustine. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is bendamustine hydrochloride.

[0241] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is doxorubicin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is doxorubicin. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is doxorubicin hydrochloride.

[0242] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is etoposide, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, prodrug, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is etoposide. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is etoposide phosphate.

[0243] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is methotrexate, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is methotrexate. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is methotrexate sodium.

[0244] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is cytarabine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is cytarabine.

[0245] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is vincristine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is vincristine. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is vincristine sulfate.

[0246] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is ifosfamide, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ifosfamide.

[0247] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is melphalan, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is melphalan. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is melphalan hydrochloride.

[0248] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is oxaliplatin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is oxaliplatin.

[0249] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is dexamethasone, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is dexamethasone.

[0250] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is BI2536, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is BI2536.

[0251] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is JQ1, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is JQ1.

[0252] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is Compound B, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound B.

[0253] In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is rac-CCT 250863, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating DLBCL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is rac-CCT 250863.

[0254] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is panobinostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is panobinostat. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is panobinostat lactate.

[0255] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is romidepsin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is romidepsin.

[0256] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is vorinostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is vorinostat.

[0257] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is citarinostat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is citarinostat.

[0258] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is venetoclax, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is venetoclax.

[0259] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is ibrutinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ibrutinib.

[0260] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is everolimus, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is everolimus.

[0261] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is idelalisib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is idelalisib.

[0262] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is enzastaurin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is enzastaurin. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is a hydrochloride salt of enzastaurin.

[0263] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is fostamatinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fostamatinib. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fostamatinib disodium hexahydrate.

[0264] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is fedratinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fedratinib.

[0265] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is pacritinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is pacritinib.

[0266] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is ruxolitinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ruxolitinib. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ruxolitinib phosphate.

[0267] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is alisertib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is alisertib.

[0268] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is tazemetostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is tazemetostat.

[0269] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK126, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK126.

[0270] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is CPI-1205, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is CPI-1205.

[0271] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is birabresib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is birabresib.

[0272] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is Compound B, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound B.

[0273] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is 5-azacytidine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is 5-azacytidine.

[0274] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is decitabine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is decitabine.

[0275] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is pinometostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is pinometostat.

[0276] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is C646, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is C646.

[0277] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is OICR-9429, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is OICR-9429.

[0278] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK3484862, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK3484862.

[0279] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is Compound C, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound C. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound C besylate.

[0280] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is seclidemstat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is seclidemstat. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is seclidemstat mesylate.

[0281] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is UNC0631, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is UNC0631.

[0282] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK3326595, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK3326595.

[0283] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is LP99, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is LP99.

[0284] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is A-196, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is A-196.

[0285] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is EZM2302, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is EZM2302.

[0286] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is bendamustine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is bendamustine. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is bendamustine hydrochloride.

[0287] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is doxorubicin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is doxorubicin. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is doxorubicin hydrochloride.

[0288] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is etoposide, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, prodrug, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is etoposide. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is etoposide phosphate.

[0289] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is methotrexate, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is methotrexate. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is methotrexate sodium.

[0290] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is cytarabine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is cytarabine.

[0291] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is vincristine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is vincristine. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is vincristine sulfate.

[0292] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is ifosfamide, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ifosfamide.

[0293] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is melphalan, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is melphalan. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is melphalan hydrochloride.

[0294] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is oxaliplatin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is oxaliplatin.

[0295] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is dexamethasone, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is dexamethasone.

[0296] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is BI2536, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is BI2536.

[0297] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is JQ1, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is JQ1.

[0298] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is Compound B, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound B.

[0299] In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is rac-CCT 250863, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating CLL / SLL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is rac-CCT 250863.

[0300] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is panobinostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is panobinostat. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is panobinostat lactate. In one embodiment, the AML is B-cell AML.

[0301] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is romidepsin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is romidepsin. In one embodiment, the AML is B-cell AML.

[0302] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is vorinostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is vorinostat. In one embodiment, the AML is B-cell AML.

[0303] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is citarinostat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is citarinostat. In one embodiment, the AML is B-cell AML.

[0304] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is venetoclax, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is venetoclax. In one embodiment, the AML is B-cell AML.

[0305] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is ibrutinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ibrutinib. In one embodiment, the AML is B-cell AML.

[0306] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is everolimus, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is everolimus. In one embodiment, the AML is B-cell AML.

[0307] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is idelalisib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is idelalisib. In one embodiment, the AML is B-cell AML.

[0308] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is enzastaurin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is enzastaurin. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is a hydrochloride salt of enzastaurin. In one embodiment, the AML is B-cell AML.

[0309] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is fostamatinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fostamatinib. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fostamatinib disodium hexahydrate. In one embodiment, the AML is B-cell AML.

[0310] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is fedratinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fedratinib. In one embodiment, the AML is B-cell AML.

[0311] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is pacritinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is pacritinib. In one embodiment, the AML is B-cell AML.

[0312] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is ruxolitinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ruxolitinib. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ruxolitinib phosphate. In one embodiment, the AML is B-cell AML.

[0313] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is alisertib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is alisertib. In one embodiment, the AML is B-cell AML.

[0314] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is tazemetostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is tazemetostat. In one embodiment, the AML is B-cell AML.

[0315] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK126, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK126. In one embodiment, the AML is B-cell AML.

[0316] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is CPI-1205, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is CPI-1205. In one embodiment, the AML is B-cell AML.

[0317] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is birabresib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is birabresib. In one embodiment, the AML is B-cell AML.

[0318] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is Compound B, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound B. In one embodiment, the AML is B-cell AML.

[0319] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is 5-azacytidine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is 5-azacytidine. In one embodiment, the AML is B-cell AML.

[0320] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is decitabine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is decitabine. In one embodiment, the AML is B-cell AML.

[0321] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is pinometostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is pinometostat. In one embodiment, the AML is B-cell AML.

[0322] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is C646, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is C646. In one embodiment, the AML is B-cell AML.

[0323] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is OICR-9429, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is OICR-9429. In one embodiment, the AML is B-cell AML.

[0324] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK3484862, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK3484862. In one embodiment, the AML is B-cell AML.

[0325] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is Compound C, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound C. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound C besylate. In one embodiment, the AML is B-cell AML.

[0326] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is seclidemstat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is seclidemstat. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is seclidemstat mesylate. In one embodiment, the AML is B-cell AML.

[0327] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is UNC0631, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof i(e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is UNC0631. In one embodiment, the AML is B-cell AML.

[0328] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK3326595, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK3326595. In one embodiment, the AML is B-cell AML.

[0329] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is LP99, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is LP99. In one embodiment, the AML is B-cell AML.

[0330] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is A-196, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof i(e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is A-196. In one embodiment, the AML is B-cell AML.

[0331] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is EZM2302, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is EZM2302. In one embodiment, the AML is B-cell AML.

[0332] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is bendamustine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof i(e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is bendamustine. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is bendamustine hydrochloride. In one embodiment, the AML is B-cell AML.

[0333] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is doxorubicin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is doxorubicin. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is doxorubicin hydrochloride. In one embodiment, the AML is B-cell AML.

[0334] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is etoposide, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, prodrug, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is etoposide. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is etoposide phosphate. In one embodiment, the AML is B-cell AML.

[0335] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is methotrexate, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is methotrexate. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is methotrexate sodium. In one embodiment, the AML is B-cell AML.

[0336] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is cytarabine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is cytarabine. In one embodiment, the AML is B-cell AML.

[0337] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is vincristine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is vincristine. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is vincristine sulfate. In one embodiment, the AML is B-cell AML.

[0338] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is ifosfamide, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ifosfamide. In one embodiment, the AML is B-cell AML.

[0339] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is melphalan, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is melphalan. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is melphalan hydrochloride. In one embodiment, the AML is B-cell AML.

[0340] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is oxaliplatin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is oxaliplatin. In one embodiment, the AML is B-cell AML.

[0341] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is dexamethasone, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is dexamethasone. In one embodiment, the AML is B-cell AML.

[0342] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is BI2536, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is BI2536. In one embodiment, the AML is B-cell AML.

[0343] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is JQ1, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is JQ1. In one embodiment, the AML is B-cell AML.

[0344] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is Compound B, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound B. In one embodiment, the AML is B-cell AML.

[0345] In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is rac-CCT 250863, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating AML, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is rac-CCT 250863. In one embodiment, the AML is B-cell AML.

[0346] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is panobinostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is panobinostat. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is panobinostat lactate.

[0347] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is romidepsin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is romidepsin.

[0348] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is vorinostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is vorinostat.

[0349] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is citarinostat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is citarinostat.

[0350] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is venetoclax, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is venetoclax.

[0351] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is ibrutinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ibrutinib.

[0352] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is everolimus, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is everolimus.

[0353] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is idelalisib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is idelalisib.

[0354] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of A, in combination with a second active agent, wherein the second active agent is enzastaurin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is enzastaurin. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is a hydrochloride salt of enzastaurin.

[0355] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is fostamatinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fostamatinib. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fostamatinib disodium hexahydrate.

[0356] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is fedratinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fedratinib.

[0357] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is pacritinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is pacritinib.

[0358] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is ruxolitinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ruxolitinib. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ruxolitinib phosphate.

[0359] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is alisertib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is alisertib.

[0360] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is tazemetostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is tazemetostat.

[0361] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK126, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK126.

[0362] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is CPI-1205, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is CPI-1205.

[0363] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is birabresib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is birabresib.

[0364] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is Compound B, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound B.

[0365] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is 5-azacytidine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is 5-azacytidine.

[0366] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is decitabine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is decitabine.

[0367] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is pinometostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is pinometostat.

[0368] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is C646, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is C646.

[0369] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is OICR-9429, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is OICR-9429.

[0370] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK3484862, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK3484862.

[0371] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is Compound C, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound C. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound C besylate.

[0372] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is seclidemstat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is seclidemstat. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is seclidemstat mesylate.

[0373] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is UNC0631, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is UNC0631.

[0374] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK3326595, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK3326595.

[0375] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is LP99, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof i(e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is LP99.

[0376] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is A-196, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is A-196.

[0377] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is EZM2302, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is EZM2302.

[0378] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is bendamustine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is bendamustine. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is bendamustine hydrochloride.

[0379] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is doxorubicin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is doxorubicin. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is doxorubicin hydrochloride.

[0380] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is etoposide, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, prodrug, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is etoposide. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is etoposide phosphate.

[0381] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is methotrexate, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is methotrexate. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is methotrexate sodium.

[0382] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is cytarabine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is cytarabine.

[0383] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is vincristine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is vincristine. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is vincristine sulfate.

[0384] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is ifosfamide, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ifosfamide.

[0385] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is melphalan, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is melphalan. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is melphalan hydrochloride.

[0386] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is oxaliplatin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is oxaliplatin.

[0387] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is dexamethasone, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is dexamethasone.

[0388] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is BI2536, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is BI2536.

[0389] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is JQ1, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is JQ1.

[0390] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is Compound B, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound B.

[0391] In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is rac-CCT 250863, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating ALL, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is rac-CCT 250863.

[0392] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is panobinostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is panobinostat. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is panobinostat lactate.

[0393] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is romidepsin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is romidepsin.

[0394] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is vorinostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is vorinostat.

[0395] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is citarinostat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is citarinostat.

[0396] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is venetoclax, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is venetoclax.

[0397] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is ibrutinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ibrutinib.

[0398] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is everolimus, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is everolimus.

[0399] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is idelalisib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is idelalisib.

[0400] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is enzastaurin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is enzastaurin. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is a hydrochloride salt of enzastaurin.

[0401] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is fostamatinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fostamatinib. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fostamatinib disodium hexahydrate.

[0402] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is fedratinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is fedratinib.

[0403] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is pacritinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is pacritinib.

[0404] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is ruxolitinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ruxolitinib. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is ruxolitinib phosphate.

[0405] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is alisertib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is alisertib.

[0406] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is tazemetostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is tazemetostat.

[0407] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK126, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK126.

[0408] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is CPI-1205, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is CPI-1205.

[0409] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is birabresib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is birabresib.

[0410] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is Compound B, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound B.

[0411] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is 5-azacytidine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is 5-azacytidine.

[0412] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is decitabine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is decitabine.

[0413] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is pinometostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is pinometostat.

[0414] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is C646, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is C646.

[0415] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is OICR-9429, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is OICR-9429.

[0416] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK3484862, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof i(e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK3484862.

[0417] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is Compound C, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound C. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is Compound C besylate.

[0418] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is seclidemstat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is seclidemstat. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is seclidemstat mesylate.

[0419] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is UNC0631, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is UNC0631.

[0420] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is GSK3326595, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is GSK3326595.

[0421] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is LP99, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is LP99.

[0422] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is A-196, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is A-196.

[0423] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is EZM2302, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is EZM2302.

[0424] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is bendamustine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is bendamustine. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is bendamustine hydrochloride.

[0425] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is doxorubicin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is doxorubicin. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is doxorubicin hydrochloride.

[0426] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is etoposide, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, prodrug, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is etoposide. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent is etoposide phosphate.

[0427] In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound A, in combination with a second active agent, wherein the second active agent is methotrexate, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof. In one embodiment, provided herein is a method of treating MM, which comprises administering to a patient a therapeutically effective amount of Compound 1 or pharmaceutically acceptable salt thereof (e.g., a hydrochloride salt of Compound 1), in combination with a second active agent, wherein the second active agent i...

Claims

1. A compound for use in a method of treating a hematological malignancy, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of the compound in combination with a second active agent, wherein the compound is Compound 1: or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof; and wherein the second active agent is one or more of an EZH2 inhibitor, an HDAC inhibitor, a BCL2 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PI3K inhibitor, a PKCβ inhibitor, a SYK inhibitor, a JAK2 inhibitor, an Aurora kinase inhibitor, a BET inhibitor, a hypomethylating agent, a DOT1L inhibitor, a HAT inhibitor, a WDR5 inhibitor, a DNMT1 inhibitor, an LSD-1 inhibitor, a G9A inhibitor, a PRMT5 inhibitor, a BRD inhibitor, a SUV420H1 / H2 inhibitor, a CARM1 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an MEK inhibitor, a PHF19 inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, or a BIRC5 inhibitor.

2. A second active agent for use in a method of treating a hematological malignancy, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of a compound in combination with the second active agent, wherein the compound is Compound 1: or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof; and wherein the second active agent is one or more of an EZH2 inhibitor, an HDAC inhibitor, a BCL2 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PI3K inhibitor, a PKCβ inhibitor, a SYK inhibitor, a JAK2 inhibitor, an Aurora kinase inhibitor, a BET inhibitor, a hypomethylating agent, a DOT1L inhibitor, a HAT inhibitor, a WDR5 inhibitor, a DNMT1 inhibitor, an LSD-1 inhibitor, a G9A inhibitor, a PRMT5 inhibitor, a BRD inhibitor, a SUV420H1 / H2 inhibitor, a CARM1 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an MEK inhibitor, a PHF19 inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, or a BIRC5 inhibitor.

3. A compound and a second active agent for use in a method of treating a hematological malignancy, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of the compound in combination with the second active agent, wherein the compound is Compound 1: or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof; and wherein the second active agent is one or more of an EZH2 inhibitor, an HDAC inhibitor, a BCL2 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PI3K inhibitor, a PKCβ inhibitor, a SYK inhibitor, a JAK2 inhibitor, an Aurora kinase inhibitor, a BET inhibitor, a hypomethylating agent, a DOT1L inhibitor, a HAT inhibitor, a WDR5 inhibitor, a DNMT1 inhibitor, an LSD-1 inhibitor, a G9A inhibitor, a PRMT5 inhibitor, a BRD inhibitor, a SUV420H1 / H2 inhibitor, a CARM1 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an MEK inhibitor, a PHF19 inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, or a BIRC5 inhibitor.

4. The compound and / or second active agent for use of any one of claims 1-3, wherein the second active agent is an EZH2 inhibitor.

5. The compound and / or second active agent for use of claim 4, wherein the EZH2 inhibitor is tazemetostat, GSK126, CPI-1205, 3-deazaneplanocin A (DZNep), EPZ005687, EI1, UNC1999, or sinefungin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof.

6. The compound and / or second active agent for use of claim 5, wherein the EZH2 inhibitor is tazemetostat, GSK126, or CPI-1205.

7. The compound and / or second active agent for use of claim 6, wherein the EZH2 inhibitor is tazemetostat.

8. The compound and / or second active agent for use of any one of claims 1-3, wherein (a) the second active agent is an HDAC inhibitor, optionally (a)(i) wherein the HDAC inhibitor is panobinostat, romidepsin, or vorinostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the HDAC inhibitor is panobinostat, panobinostat lactate, romidepsin, or vorinostat; or (a)(ii) wherein the HDAC inhibitor is a HDAC6 inhibitor, for example wherein the HDAC6 inhibitor is citarinostat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof, optionally wherein the HDAC6 inhibitor is citarinostat; or (b) the second active agent is a BCL2 inhibitor, optionally wherein the BCL2 inhibitor is venetoclax, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the BCL2 inhibitor is venetoclax; or (c) the second active agent is a BTK inhibitor, optionally wherein the BTK inhibitor is ibrutinib, or acalabrutinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the BTK inhibitor is ibrutinib; or (d) the second active agent is an mTOR inhibitor, optionally wherein the mTOR inhibitor is rapamycin or an analog thereof (also termed rapalog), for example wherein the mTOR inhibitor is everolimus; or (e) the second active agent is a PI3K inhibitor, optionally wherein the PI3K inhibitor is idelalisib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the PI3K inhibitor is idelalisib; or (f) the second active agent is a PKCβ inhibitor, optionally wherein the PKCβ inhibitor is enzastaurin, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the PKCβ inhibitor is enzastaurin or a hydrochloride salt of enzastaurin; or (g) the second active agent is a SYK inhibitor; optionally wherein the SYK inhibitor is fostamatinib, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the SYK inhibitor is fostamatinib or fostamatinib disodium hexahydrate; or (h) the second active agent is a JAK2 inhibitor, optionally wherein the JAK2 inhibitor is fedratinib, pacritinib, ruxolitinib, baricitinib, gandotinib, lestaurtinib, or momelotinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the JAK2 inhibitor is fedratinib, pacritinib, ruxolitinib, or ruxolitinib phosphate; or (i) the second active agent is an Aurora kinase inhibitor; optionally (i)(i) wherein the Aurora kinase inhibitor is alisertib, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the Aurora kinase inhibitor is alisertib; or (i)(ii) wherein the Aurora kinase inhibitor is barasertib, AZD1152-HQPA, danusertib, AT9283, PF-03814735, AMG900, tozasertib, ZM447439, MLN8054, hesperidin, SNS-314, PHA-680632, CYC116, GSK1070916, TAK-901, or CCT137690, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof; or (j) the second active agent is a BET inhibitor, optionally wherein the BET inhibitor is birabresib or 4-[2-(cyclopropylmethoxy)-5-(methanesulfonyl)phenyl]-2-methylisoquinolin-1(2H)-one, BMS-986158, RO-6870810, CPI-0610, or molibresib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the BET inhibitor is birabresib or 4-[2-(cyclopropylmethoxy)-5-(methanesulfonyl)phenyl]-2-methylisoquinolin-1(2H)-one; or (k) the second active agent is a hypomethylating agent, optionally wherein the hypomethylating agent is 5-azacytidine or decitabine, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the hypomethylating agent is 5-azacytidine or decitabine; or (l) the second active agent is a DOT1L inhibitor, optionally wherein the DOT1L inhibitor is SGC0946, or pinometostat, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the DOT1L inhibitor is pinometostat; or (m) the second active agent is a HAT inhibitor, optionally wherein the HAT inhibitor is C646, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the HAT inhibitor is C646; or (n) the second active agent is a WDR5 inhibitor, optionally wherein the WDR5 inhibitor is OICR-9429, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the WDR5 inhibitor is OICR-9429; or (o) the second active agent is a DNMT1 inhibitor, optionally wherein the DNMT1 inhibitor is a DNMT1 selective inhibitor, for example wherein the DNMT1 selective inhibitor is GSK3484862, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, optionally wherein the DNMT1 selective inhibitor is GSK3484862; or (p) the second active agent is an LSD-1 inhibitor, optionally wherein the LSD-1 inhibitor is 4-(2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile or seclidemstat, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the LSD-1 inhibitor is 4-(2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)- 1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile, 4-(2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile besylate, seclidemstat, or seclidemstat mesylate; or (q) the second active agent is a G9A inhibitor, optionally wherein the G9A inhibitor is UNC0631, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the G9A inhibitor is UNC0631; or (r) the second active agent is a PRMT5 inhibitor, optionally wherein the PRMT5 inhibitor is GSK3326595, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the PRMT5 inhibitor is GSK3326595; or (s) the second active agent is a BRD inhibitor, optionally (s)(i) wherein the BRD inhibitor is a BRD9 / 7 inhibitor, for example wherein the BRD9 / 7 inhibitor is LP99, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, optionally wherein the BRD9 / 7 inhibitor is LP99; or (s)(ii) wherein the BRD inhibitor is a BRD4 inhibitor, optionally wherein the BRD4 inhibitor is JQ1; or (t) the second active agent is a SUV420H1 / H2 inhibitor, optionally wherein the SUV420H1 / H2 inhibitor is A-196, or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the SUV420H1 / H2 inhibitor is A 196; or (u) the second active agent is a CARM1 inhibitor, optionally wherein the CARM1 inhibitor is EZM2302, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, for example wherein the CARM1 inhibitor is EZM2302; or (v) the second agent is a PLK1 inhibitor, optionally wherein the PLK1 inhibitor is BI2536, volasertib, CYC140, onvansertib, GSK461364, or TAK960, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof; or (w) the second agent is an NEK2 inhibitor, optionally wherein the NEK2 inhibitor is JH-295 or rac-CCT 250863; or (x) the second agent is an MEK inhibitor, optionally (x)(i) wherein the MEK inhibitor interrupts the function of the RAF / RAS / MEK signal transduction cascade; or (x)(ii) wherein the MEK inhibitor is trametinib, trametinib dimethyl sulfoxide, cobimetinib, binimetinib, or selumetinib, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof; or (y) the second agent is a PHF19 inhibitor; or (z) the second active agent is a PIM inhibitor, optionally wherein the PIM inhibitor is LGH-447, AZD1208, SGI-1776, or TP-3654, or a stereoisomer, mixture of stereoisomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof; or (aa) the second active agent is an IGF-1R inhibitor, optionally wherein the IGF-1R inhibitor is linsitinib; or (ab) the second active agent is an XPO1 inhibitor, optionally wherein the XPO1 inhibitor is selinexor; or (ac) the second active agent is a BIRC5 inhibitor, optionally wherein the BIRC5 inhibitor is YM155.

9. The compound and / or second active agent for use of any one of claims 1 to 8, wherein the compound is a hydrochloride salt of Compound 1.

10. The compound and / or second active agent for use of any one of claims 1 to 9, wherein the hematological malignancy is acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma (HL), T-cell lymphoma (TCL), Burkitt lymphoma (BL), chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), marginal zone lymphoma (MZL), or myelodysplastic syndromes (MDS).

11. The compound and / or second active agent for use of claim 10, wherein the hematological malignancy is relapsed or refractory.

12. The compound and / or second active agent for use of claim 10, wherein the hematological malignancy is newly diagnosed.

13. The compound and / or second active agent for use of claim 10, wherein the hematological malignancy is DLBCL, optionally (a) wherein the DLBCL is relapsed or refractory DLBCL, for example wherein the DLBCL is refractory to one or more of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide, bendamustine, lenalidomide, or gemcitabine; or (b) wherein the DLBCL is newly diagnosed DLBCL.

14. The compound and / or second active agent for use of claim 10, wherein the hematological malignancy is CLL / SLL, optionally (a) wherein the CLL / SLL is relapsed or refractory CLL / SLL, for example wherein the CLL / SLL is relapsed or refractory to at least two prior therapies, optionally wherein at least one of the prior therapies is a Bruton's tyrosine kinase (BTK) inhibitor, for example wherein the BTK inhibitor is ibrutinib, acalabrutinib, zanubrutinib, or tirabrutinib; or (b) wherein the CLL / SLL is newly diagnosed.

15. The compound and / or second active agent for use of claim 10, wherein the hematological malignancy is (a) AML, and the AML is B-cell AML; (b) multiple myeloma, and the multiple myeloma is plasma cell leukemia (PCL); (c) TCL, and the TCL is anaplastic large cell lymphoma (ALCL) or Sezary Syndrome; or (d) MZL, and the MZL is splenic marginal zone lymphoma (SMZL).